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Abstract 
 Adjuvant chemotherapy is an essential component in the treatment of advanced colorectal 
cancer (CRC). Unfortunately, many patients experience recurrence with aggressive, 
chemotherapy-resistant disease for which the prognosis is poor and treatment options are limited. 
Understanding the changes that cancer cells undergo during the acquisition of a drug-resistant 
phenotype is therefore of critical importance in improving CRC patient outcomes. We chose to 
study resistance to the CRC chemotherapy agent, irinotecan, by first creating a CRC cell line that 
is highly resistant to its active metabolite (SN-38). In particular, we were interested in how SN-
38 resistant CRC cells (HT-29S) were altered from parental, drug-sensitive CRC cells (HT-29) in 
their relationship with a feature of their microenvironment, the extracellular matrix (ECM). We 
found that HT-29S cells form a matrix composed of the ECM glycoprotein fibronectin when 
cultured as 3-dimensional spheroids, whereas HT-29 cells do not. The increase in fibronectin 
matrix deposition coincided with an increased fibronectin adhesive capacity of the SN-38-
resistant cells, likely due to an increased expression of the integrin α5 subunit, which together 
with integrin β1 forms the primary fibronectin receptor. Furthermore, we demonstrated an 
activation of a phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt) pro-survival signalling 
pathway downstream of integrin α5β1 ligation to fibronectin. Inhibition of this signalling 
pathway with the PI3K inhibitor LY294002 sensitized HT-29S cells to SN-38, but did not alter 
the response of the parental cell line to the chemotherapy agent. Finally, we have determined that 
HT-29S cells appear to undergo an epithelial to mesenchymal transition during the acquisition of 
chemotherapy resistance, and that this transition may be responsible for the upregulation of 
integrin α5 in the resistant population.  
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Chapter 1: Introduction 
1.1 Colorectal Cancer 
 1.1.1 Background 
Malignancies that originate in the epithelial cell layer of the colon or rectum are 
collectively known as colorectal cancers (CRCs). These cancers represent a significant disease 
burden as the most recent available data indicates that CRC is second only to lung cancers as a 
cause of cancer-related deaths among Canadians1. This is partially due to the high prevalence of 
the disease, as CRC is the second and third most commonly diagnosed form of cancer in male 
and female Canadians respectively1. A decline in the incidence and increase in relative survival 
has been observed for CRC in recent years, however these observations are generally attributed 
to improved screening for early-stage tumours rather than improved therapies1. There is therefore 
a significant need for improvement at the treatment stage of CRC management.  
1.1.2. Colorectal Cancer Therapy 
 The recommended treatment(s) for CRC is largely dependent upon the stage at which the 
disease is detected and diagnosed. Pre-cancerous polyps and very early stage tumours are often 
curable with surgical resection of the neoplasm, without any requirement for adjuvant (post-
surgery) chemotherapy. However as the cancer progresses into a later stage, the addition of 
chemotherapy offers a potentially significant survival benefit, as has been demonstrated in a 
number of large-scale clinical trials at various stages and using different chemotherapy 
regimens2–6. The backbone of most CRC chemotherapy regimens is 5-fluorouracil (5-FU)7; a 
uracil analogue which has numerous activities, including inhibition of thymidylate synthase (TS) 
and incorporation into RNA (reviewed in 8). 5-FU is usually administered in combination with 
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leucovorin, which enhances the activity of 5-FU by increasing the available 5’-
formyltetrahydrofolate within the cell8. Clinical trials have demonstrated a survival benefit in 
CRC patients treated with 5-FU, with or without leucovorin2,4,5. Very advanced CRC patients are 
often treated with another chemotherapy agent, in addition to 5-FU and leucovorin, oxaliplatin7. 
Oxaliplatin is a platinum-based drug which is thought to form adducts with cellular DNA, 
causing lethal damage to the cell9. The addition of oxaliplatin to a CRC treatment regimen has 
been validated in several very large clinical trials to significantly improve patient survival10,11. 
The third main chemotherapy agent used in treating CRC is irinotecan, a topoisomerase I 
(TopoI) inhibitor that has demonstrated efficacy in treating very advanced and metastatic CRC, 
including in patients for whom 5-FU has failed12–14. Chemotherapy may also provide a palliative 
benefit in patients with very advanced, disseminated disease where a curative approach is not 
feasible7,14–16. Chemotherapy agents are therefore essential to adequately treat advanced, 
aggressive CRCs. 
1.2 Irinotecan and  
Topoisomerase Inhibitors 
 1.2.1 Camptothecin Family 
Irinotecan is a derivative of 
the natural product alkaloid 
camptothecin, which was originally 
isolated from the bark of the 
Camptotheca acuminata tree17. 
Camptothecin and its derivatives 
exert their anti-cancer effects 
Figure 1.1: Camptothecin family of TopoI inhibitors. 
The chemical structures of camptothecin, irinotecan, and 
SN-38 are shown above. Images were constructed using 
the open source web-based program MolView. 
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through inhibition of TopoI18. DNA transcription and replication require the separation of the 
two DNA strands, which introduces supercoiling into the molecule. TopoI enzymes are able to 
introduce single strand breaks into DNA, which allow unwinding to occur and relieve the 
supercoiling-induced strain. TopoI is then able to repair the DNA break it previously 
introduced19.  
Camptothecin family members poison TopoI activity by stabilizing the TopoI-DNA 
interaction, forming a “cleavable complex” and preventing repair of TopoI-introduced single 
strand breaks18. During DNA synthesis, advancing replication forks collide with these trapped 
cleavable complexes and convert them into double strand DNA breaks, which is lethal to the 
cell20–22. TopoI’s mechanism of action and inhibition by camptothecins is outlined in figure 1.2. 
The dependence on DNA synthesis to generate DNA damage with camptothecin 
treatment is supported by observations that camptothecin treatment mostly targets cells in the S-
phase of the cell cycle, and that the effects of camptothecins can be blocked by simultaneous 
treatment with inhibitors of DNA synthesis23,24. More recent studies however have demonstrated 
that camptothecins are also capable of inducing apoptosis in quiescent, non-dividing cells such as 
neurons25. This non-S-phase cytotoxicity likely involves camptothecin-mediated inhibition of 
transcription elongation, which has been previously observed26 and is probably a result of a 
collision between trapped TopoI and RNA polymerase II on the template strand27.   
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Figure 1.2: TopoI-mediated removal of torsional strain in DNA. 
1. TopoI binds to DNA experiencing torsional strain during replication or transcription. 
2. The TopoI enzyme introduces a single strand break in the DNA. 
3. DNA rotates around the single strand break to unwind and relieve the torsional strain. 
4. TopoI repairs the single strand break and separates from the DNA. Camptothecin 
blocks the repair and traps TopoI on the DNA. 
These images are adapted from Servier Medical Art by Servier, licensed under CC BY 3.0. 
TopoI ribbon structure generated by the open source software MolView. 
1. 
2. 
3. 
TopoI 
4. Camptothecin 
Cleavable complex 
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1.2.2. Use of Irinotecan in Colorectal Cancer Therapy 
 Camptothecin’s development into an anti-cancer agent was unfortunately limited by its 
poor solubility and excessive toxicity (reviewed in 28) and so derivatives of camptothecin were 
developed instead. One such derivative that retained camptothecin’s powerful anti-cancer 
properties while being better tolerated and more soluble was the aforementioned CRC 
chemotherapy agent, irinotecan29. Despite impressive activity against murine tumours, it was 
demonstrated that irinotecan had little direct anti-cancer activity; the in vitro half-maximal 
concentration (EC50) (i.e. the concentration of the compound that elicited a response halfway 
between the baseline and maximum possible response) of irinotecan was found to be >1000-fold 
that of camptothecin30. However, incubating irinotecan in mouse serum or tissue homogenate 
resulted in the conversion of the drug to a metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38) 
which showed anti-cancer effects of similar potency to camptothecin itself30. Further studies 
confirmed the metabolism of irinotecan to SN-38 in human serum31, as well as identified its 
conversion within the liver32, small intestine (and to a lesser degree, the colon)33, and even by 
select cancer cell lines34 by carboxylesterase (CE) eznymes35.  
Irinotecan metabolism in vivo is complex. SN-38 is further metabolised within the liver 
by conjugation to a glucuronic acid moiety to form SN-38 glucuronide (SN-38G)36–38, a step 
which is believed to aid in detoxification and excretion of the drug39. SN-38G may however be 
converted back to active SN-38 to a significant degree within the lumen of the ileum and colon 
by β-glucuronidases produced by the resident microflora40. This reclaimed SN-38 appears to 
contribute to the toxic side effects of the drug, which centre around gastrointestinal distress 
involving diarrhea40. Irinotecan may also be converted to two additional inactive derivatives by 
cytochrome P450 (CYP) enzymes in the liver, mostly CYP3A4. These derivatives are called 7-
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ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] - carbonyloxycamptothecin (APC) and 7-
ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin (NPC). SN-38, SN-38G, and 
irinotecan may all be excreted through the biliary system into the intestines by p-glycoprotein (P-
Gp) and canilicular multispecific organic anion transporter (cMOAT) enzymes35. Excretion of 
irinotecan and its metabolites mainly occurs in the feces, followed by the urine41. The in vivo 
metabolism of irinotecan as well as its major clearance routes are outlined in figure 1.3.  
  
 
Figure 1.3: Irinotecan metabolism and excretion. 
Pharmacokinetics of irinotecan (CPT-11) in vivo after intravenous administration. CPT-11 
and its metabolites are shown in bold, clearance routes in italics, and proteins in normal font.  
These images are adapted from Servier Medical Art by Servier, licensed under CC BY 3.0. 
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1.3 Chemotherapy Resistance 
1.3.1 Common resistance mechanisms 
Although chemotherapy has well-demonstrated benefits in the management of advanced 
CRC, these benefits typically only translate to a moderate improvement in survival. For example, 
the IMPACT study on 5-FU and leucovorin adjuvant chemotherapy in Dukes stage B and C 
CRC patients found that the chemotherapy-treated patients had a one-year survival of 83% 
versus 78% in the untreated group2. A similar pattern can be observed for all available 
chemotherapy agents or regimens; survival may be improved but a substantial number of patients 
will still relapse or fail to respond to therapy. Even patients who experience a complete response 
as diagnosed by X-ray computed tomography (CT) or other imaging techniques often retain 
viable cancer cells at disease sites, called minimal residual disease42. These cells may remain 
dormant during chemotherapy and for a period time afterwards, but eventually (up to months or 
years later) awaken and proliferate, causing recurrent tumours that are often more resistant to 
chemotherapy43. Furthermore, although chemotherapy improves survival of CRC patients, those 
who experience recurrence after chemotherapy face a worse prognosis than patients who were 
originally treated with surgery alone44. The development of new treatment options to specifically 
target these resistant populations would substantially improve patient outcomes, and so there is a 
pressing need to understand the changes that occur within cancer cells upon achieving 
chemotherapy resistance.  
 One common mechanism for drug resistance in cancer cells is the upregulation of efflux 
pump proteins, such as P-gp encoded by the MDR1 gene45. P-gp and other efflux pumps are able 
to transport a wide variety of compounds from the cytosol to the extracellular space or into 
lysosomes, including some chemotherapy drugs45,46. By removing a drug from the cell, efflux 
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pumps can block their activity and thus promote drug resistance. Evidence exists that efflux 
pump-mediated resistance is clinically relevant; an analysis of acute myeloid leukemia (AML) 
patients at the time of diagnosis and disease relapse found a gene-level upregulation of the breast 
cancer resistance protein (BCRP) efflux, occurred with disease progression47.  
Specific inhibitors of the various drug-efflux pumps have been developed in an attempt to 
improve patient response to chemotherapy, especially against refractory cancer. Despite 
promising pre-clinical data however, three successive generations of these inhibitors have failed 
to demonstrate a survival benefit for patients (reviewed in 48). Among the possible explanations 
for the disappointing clinical performance of these inhibitors is that alternative drug-resistance 
programs are alternatively or concurrently active in these advanced, chemo-refractory cancers. 
The strong influence of the local microenvironment on a cancer cell’s behaviour suggests that the 
microenvironment may be one of these alternative contributing factors to chemotherapy 
resistance, and so we examined the effects of the microenvironment on the behaviour of our SN-
38-resistant CRC derivatives. We were particularly interested in one component of the tumour 
microenvironment: the extracellular matrix (ECM).   
1.4 The Extracellular Matrix 
 1.4.1 Extracellular Matrix Background 
ECMs are complex interwoven networks formed from a large and diverse family of 
proteins and proteoglycans (reviewed in 49).THey They contribute to many important connective 
tissues, including bone, basement membranes, cartilage, and interstitial tissues49. There is a great 
deal of variety between the types of ECM proteins produced across metazoa, however every 
animal appears to produce at least a few ECM molecules. Drosophila melanogaster and 
Caenorhabditis elegans, for example, express the “core” basement membrane proteins type IV 
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collagen, laminin, entactin, and perlecan-type proteoglycans, but do not express the ECM 
glycoprotein fibronectin, which is found in humans and other vertebrates50. Even sponges 
express some collagens and other ECM-associated proteins51, although these are apparently 
much simpler than the ECMs found in higher animals.  
The traditional earlier view of the basement membrane and other ECMs in relation to 
cancer was that of a barrier against invasion and metastasis. While this is certainly one of the 
functions of the ECM that is relevant to the progression of the disease, it is becoming 
increasingly apparent that ECM proteins may have additional pro-cancer functions as well. The 
ECM glycoprotein fibronectin is an excellent example of this, as fibronectin upregulation in 
breast and colon cancers has been associated with disease progression, relapse, and poor overall 
survival52–54.  
 1.4.2 Fibronectin 
Fibronectin was discovered as a fibroblast-derived protein in a pair of publications 
released in 1973, by Erkki Ruoslahti and Richard Hynes. The former demonstrated that chicken 
fibroblasts produced a surface antigen that was also remarkably abundant in the animal’s 
serum55, while the latter published a set of radiolabelling experiments identifying a large 
extracellular protein in hamster and human fibroblast cell lines56. Fibronectin was at this point 
known by a variety of names, includes “large, extracellular, transformation-sensitive” (LETS) 
and “soluble fibroblast surface antigen” (SFA) but the precise nature of the protein was not well 
understood57,58.  
Electron microscopy and immunofluorescence experiments on the newly-discovered 
ECM protein revealed its fibrous nature59, and a co-localization of these extracellular fibres with 
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actin microfilaments within the cytosol60–62, suggesting a functional link between the two. This 
link was proposed to be an integral membrane protein connecting fibronectin fibrils and the actin 
cytoskeleton58. It is now known that the integrin family of cell surface receptors establishes this 
link between fibronectin (along with other ECM proteins) and the cytoskeleton. 
1.5 Integrin Family of Cell-Surface Receptors 
1.5.1 Discovery of the Integrin Family 
Several years after the discovery of fibronectin, it was demonstrated that a certain 
antibody against the “cell substrate attachment” (CSAT) antigen was capable of blocking the 
adhesion of cells to fibronectin and other ECM proteins63. The CSAT antibody, when coated 
onto the wells of a tissue culture plate, was also capable of promoting adhesion of cells to the 
plate63. This suggested that the CSAT antigen was not on the ECM proteins themselves but was 
instead a receptor expressed on the cell surface. This hypothesis was confirmed when the CSAT 
antigen was successfully cloned and demonstrated to be a transmembrane protein64. The new 
protein was named “integrin” (now known as integrin β1) to reflect its status as an integral 
membrane protein. Homologues of integrin had already been suggested and were very soon also 
cloned, starting with integrin β2 from leukocytes and splenic tissue65,66. Thus, the integrin 
superfamily of transmembrane ECM receptors was born.  
1.5.2 Function of the Integrins 
 As integrins are the primary receptors for the various constituents of the ECM, it is not 
surprising to learn that they are also highly conserved across the metazoa. Genetic studies have 
demonstrated the existence of integrin homologues in drosophila, nematodes, coral, and 
sponges50,67. Much like the limited repertoire of ECM components in these lower animals 
however, there are far fewer integrin family members in these organisms than are found in 
11 
 
mammals and other vertebrates; humans have 18 known integrin α subunits, compared to five in 
drosophila and only two in nematodes50. Possible homologues to animal integrins have been 
detected in a protist species believed to be ancestral to animals and fungi, suggesting that 
integrins first developed in these species and were subsequently lost in fungi and other non-
animal descendants68.  
It is now known that integrins function as are heterodimers formed from an α and β 
subunit; different combinations of subunits create distinct receptors with particular sets of 
ligands, tissue tropisms, and downstream functions69,70. Integrin heterodimers not only anchor 
cells to particular ECM substrates, but also transduce information about the extracellular 
environment across the membrane to the interior of the cell, initiating intracellular signalling 
pathways and altering cellular behaviour. 
1.5.3 Inside-out versus Outside-in Signalling 
In contrast to the classical “outside-in” pathway, it is also possible for integrins to 
transmit information about a cell’s current state to the extracellular environment in a reversed, 
“inside-out” fashion. Intracellular events can “activate” an integrin dimer by introducing 
conformational changes that alter the affinity of the receptor for its ligands71. In the low affinity, 
inactive state, the β-subunit is tilted towards the α-subunit in a stable conformation maintained 
by intramembrane bonds between the two71. Activation of the integrin involves shifting of the β-
subunit away from the α-subunit to form the high-affinity “active” receptor71. Certain adapter 
proteins that interact with the cytoplasmic tail of the β-integrins, such as talin or the various 
kindlin kinases, appear to be involved in the activation process as overexpression of these 
proteins can result in spontaneous integrin activation72–74. Inside-out signaling is important for 
many cellular events, such as leukocyte diapedesis in response to inflammation75 (reviewed in 76) 
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or response to DNA-damage induced by ionizing radiation or bacterial genotoxins77. It is 
therefore important to remember that integrin activity may be as much of an expression as it is a 
determinant of a cell’s behaviour. 
1.5.4 Influence of Integrins on Cell Behaviour 
 As a highly conserved family of proteins with many different members, it is not 
surprising that integrins have important and far-reaching effects on cellular behaviour. These 
effects range from anchoring epithelial sheets to basement membranes, promoting the normal 
development of tissues, directing wound-healing in damaged tissues, and even controlling the 
migration of normally non-adherent cells such as leukocytes. Part of the reason for the wide 
variety of integrin functions is the large size of the family; mammals have 18 α and 8 β subunits 
forming 24 known heterodimers. Furthermore, any one of these heterodimers can have multiple 
ligands and effects on cell behaviour. As an example, integrin α9β1 has been demonstrated to 
promote the differentiation of hematopoietic stem cells in response to cytokines78, to coordinate 
embryonic lymphatic leaflet development in concert with a splice variant of fibronectin79, to 
promote nitrous oxide formation that enhances cellular migration80, and to support lymphocyte 
egress from lymph nodes under inflammation, without being expressed on the lymphocytes 
themselves81.  
1.5.5 The Role of Integrins in Cancer 
Many of the conventional functions of integrins, such as promoting cell migration or 
survival, are also functions that are frequently co-opted by a tumour to promote its own growth 
or to enable aid in metastasis. For example, both of the integrin receptors α2β1 and α5β1 can 
promote CRC metastasis to the liver through interactions with their ECM ligands, type IV 
collagen and fibronectin respectively82–84, and the αVβ3 receptor for vitronectin has been 
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demonstrated to promote breast cancer invasion and metastasis in vitro and in vivo85. However, 
integrin αVβ3 also serves of an example of the anti-cancer roles this family can fulfill. Despite 
promoting metastasis, αVβ3 can supress cancer cell proliferation and tumour size, and its 
expression is repressed by the well-established pro-cancer MYC protein85. Some integrins may 
act in opposition to each other, and in certain cases this is relevant for tumour progression. For 
example, integrin α5β1has been demonstrated to promote cancer cell invasion through secretion 
of various MMPs, including MMP1 and 986,87. This can be prevented however by the activity of 
another integrin receptor, α4β1 which also binds fibronectin but at a separate site from α5β186,87. 
Of the many pro and anti-cancer effects that may be mediated through integrins, the effect of 
integrin-ECM interactions on cell survival is of particular interest in cancer. 
1.5.6 Cell Adhesion-mediated drug resistance  
 Integrin-ECM interactions may supress a specialized form of apoptosis called anoikis, 
which occurs in epithelial cells that lose their normal attachments to the underlying basement 
membrane ECM88. This function serves as a safeguard against cancer development; epithelial 
cells that detach from the basement membrane will normally undergo anoikis instead of settling 
and potentially expanding in a foreign tissue site. It is becoming increasingly clear however that 
the survival signals provided by an integrin-ECM interaction may be co-opted by cancerous cells 
to protect against other stressors, and many types of cancer have now been shown to resist 
cytotoxic chemotherapy when provided with the opportunity to form adhesions to ECM proteins. 
This co-opting of ECM-derived survival signals is known as cell adhesion-mediated drug 
resistance (CAM-DR). For example, small cell lung cancer (SCLC) cells provided with an 
exogenous source of the ECM proteins fibronectin or laminin show an increased resistance to a 
number of chemotherapy agents, including etoposide, cis-platinum, and doxorubicin, as well as 
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to ionizing radiation89,90. This effect occurred through prevention of apoptosis induction by 
activation of a phosphoinositide-3-kinase (PI3K)/glycogen synthase kinase 3 beta (GSK3β) 
pathway and was not achieved with poly-L-lysine, a non-ECM-derived adhesive substrate90. 
Similarly, AML cells provided with exogenous fibronectin were more resistant to the 
chemotherapy drug daunorubicin through a PI3K/GSK3β but not focal adhesion kinase (FAK) 
dependent pathway, an effect which was attributed to the α5β1 and α4β1 integrins91. Integrin 
α4β1 may also contribute to cytosine arabinoside (AraC) resistance and minimal residual disease 
following therapy in AML patients by supporting survival of leukemic cells in the bone marrow 
stroma92. Stratifying AML patients by their α4β1 status revealed that α4β1-negative patients had 
a significantly better overall and disease-free survival than α4β1 positive patients92. Adhesion of 
multiple myeloma cells to fibronectin promoted resistance to doxorubicin, and serial passage of 
myeloma cells in the presence of doxorubicin or the alkylating agent melphalan generated 
resistant derivatives to these drugs that had an enhanced expression of the integrin α4, β1, and β7 
subunits93. Notably, the resistance programs in these cells did not appear to involve the drug 
pumps described in section 1.3.1, as there was no observed change in intracellular drug 
accumulation or efflux93. Ovarian and breast cancer cells challenged with docetaxel were also 
able to partially resist the cytotoxic effects of the drug when allowed to adhere to fibronectin 
through activation of Akt and upregulation of the anti-apoptotic protein, survivin94. However, the 
cellular receptor involved in mediating this effect was not identified by the study94. Another 
series of experiments in ovarian cancer cells showed that knockdown of the β1 integrin could 
enhance the anticancer effects of bevacizumab by supressing a FAK/signal transducer and 
activator of transcription 1 (STAT1) signalling pathway95. In this case however, the authors did 
not identify the α integrin subunit(s) or ECM components involved95. Thus, while there is data 
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supporting CAM-DR as a powerful mode of chemotherapy resistance in several types of cancer, 
many studies have failed to fully identify the integrin subunits and ECM proteins involved. 
Furthermore, CAM-DR has often been studied in the context of transient, spontaneous resistance 
upon provision of exogenous ECMs, rather than as an acquired trait. The role of CAM-DR has 
also not been adequately studied for all types of cancer or chemotherapy agents, including CRC 
and irinotecan.  
1.6 Integrin α5 
1.6.1 Background 
 One integrin subunit that has recently garnered significant attention in cancer is α5, 
which forms a single known heterodimer in humans with the β1 integrin subunit. The α5β1 
heterodimer is also known as the primary fibronectin receptor, and it interacts with fibronectin at 
an arginine-glycine-aspartic acid (RGD) motif present in the tenth type III repeat with relatively 
low affinity 96,97. Several other integrins are also able to bind this motif in fibronectin and other 
ECM proteins in a similar RGD-dependent manner, including αV, α8, and αIIb-containing 
heterodimers, although some other integrins known to bind fibronectin in vivo do so at a 
separate, non-RGD site within the glycoprotein(reviewed in 98). An example of this is α4β1, 
which binds fibronectin at the C-terminal connecting segment 1 (CS-1) site to leucine-aspartic 
acid-valine (LDV) motif86,87,98. Although α5β1 is not unique in its ability to bind fibronectin, or 
even the domain which it binds to, its interaction with fibronectin is substantially different from 
most integrins. The α5β1 receptor is (unlike other fibronectin-binding receptors such as αvβ1 or 
αβ3) able to construct a fibronectin matrix from soluble, folded-up fibronectin dimers99–102. The 
conversion of fibronectin into a fibrous matrix by integrin α5β1 requires the application of 
tension to unfold the soluble fibronectin dimers, and may be supported αVβ3 “anchoring” the 
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cell via an interaction with another ECM protein, vitronectin103. It has also been shown that the 
G-protein coupled receptors (GPCR) may be able to promote fibronectin matrix assembly via 
inside-out activation of integrin α5β1104. Normal colonic epithelial cells express abundant 
integrin α5, but the expression of this and other integrin subunits appear to be progressively lost 
along malignant transformation105.  
1.6.2 Anti-Cancer Effects of Integrin α5β1 
Like many of the integrins, the role of α5β1 in cancer has been somewhat controversial or 
unclear. Ectopic expression of integrin α5 in the Chinese hamster ovary (CHO) cell line resulted 
in an increased accumulation of pericellular fibronectin as well as increased adhesive capacity 
for fibronectin, but seemingly at the cost of many pro-cancer characteristics106. The transfected 
CHO cells proliferated at a lower rate, became growth arrested at lower cell densities, and were 
less capable of forming tumours when introduced into nude mice106. Other studies have 
confirmed that the overexpression of integrin α5 in cancer cell lines can repress the malignant 
behaviours of these cells. Integrin α5 was found to be highly expressed in the non-metastatic 
67NR breast cancer cell line, and poorly expressed by highly metastatic 4T1 breast cancer 
cells107. Overexpression of integrin α5 in 4T1 reduces the migration, invasion, and pulmonary 
metastasis of these cells, and transfection of α5 into these cells results in G1/S checkpoint 
arrest107. A similar suppression of cellular proliferation was observed by overexpression of 
integrin α5 in the CRC cell line HT-29, which does not usually express this subunit108,109. 
Aggressiveness of the cancer seemed to also be attenuated with forced integrin α5 expression; a 
significantly higher inoculum of α5-expressing HT-29 cells than parental cells were required to 
form tumours upon subcutaneous injection into nude mice, and the tumours that did form from 
α5-expressing cells were much more well-differentiated108. Interestingly, both of these studies 
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observed that many of the cancer-suppressing features associated forced integrin α5 expression 
could be reversed by allowing the cells to adhere to fibronectin108,109. More recently and in line 
with these results, a mass spectrometry-based proteomic study of formalin-fixed, paraffin-
embedded (FFPE) samples from 30 CRC patients at different stages demonstrated a decrease in 
integrin α5 expression during CRC progression110. Overall, there is a strong case for the anti-
cancer effect of integrin α5.  
1.6.3 Pro-Cancer Effects of Integrin α5β1 
In direct contrast to the preceding results, significant evidence has also accumulated in 
support of a pro-cancer role for the primary fibronectin receptor. Although reduction in integrin 
α5 expression has been observed by some studies during CRC progression, CRC cell lines 
stratified into groups by their aggressiveness show a substantial difference in integrin α5 
expression with the highly-aggressive CRC cell lines expressing abundant integrin α5111. It was 
also shown ectopic expression of integrin α5 in one of the less aggressive cell lines, GEO, caused 
it to become significantly more aggressive upon xenografting into nude mice111. Importantly, the 
cell line HT-29, for which integrin α5-mediated inhibition of proliferation and aggression was 
observed, was not included in this study. Recently, the pro-invasive effects of the transmembrane 
protease, serine 4 (TMPRSS4) in SW480 CRC cells has been demonstrated to be mediated 
through an upregulation of integrin α5 and increased signalling from the α5β1 receptor112. It was 
further demonstrated by immunohistochemistry studies of samples from 63 CRC patients that the 
expression of both integrin α5 and TMPRSS4 increased with CRC stage112. Integrin α5β1 has 
also been implicated to promote cancer by supporting the generation of new blood vessels within 
tumours in response to various pro-angiogenic factors including basic fibroblast growth factor 
(bFGF) or tumour necrosis factor alpha (TNFα)113. Another study using human placental 
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multipotent mesenchymal stromal cells (hPMSCs) differentiated into endothelial-like cells has 
demonstrated a role for integrin α5β1 in angiogenesis through an interaction between the integrin 
heterodimer and fibronectin, promoting migration and capillary-like structure formation by these 
cells114. This is significant not only because angiogenesis is an essential process to tumour 
progression that is being targeted clinically, but also because it adds another consideration to the 
debate over α5β1’s contribution to cancer progression. Many studies have focused on the effects 
of α5β1 expression on the cancer cells themselves, neglecting the possibility that α5β1 on 
endothelial cells of the tumour neovasculature contributes to cancer progression.  
1.6.4 Integrin α5 as an Angiogenesis Target for Chemotherapy 
 While there is still some confusion over the precise role of integrin α5β1 in cancer 
progression - whether it serves a pro- or anti-cancer function when expressed in the malignant 
cell itself - sufficient evidence exists of the fibronectin receptor’s contribution to tumour 
angiogenesis to have warranted development of inhibitors targeting this receptor. A challenge in 
developing these inhibitors is that many integrin heterodimers recognize the same RGD motif in 
fibronectin and other ECM proteins as integrin α5β1. However, a phage display strategy has 
been used to develop a cyclic peptide which binds integrin α5 with far greater affinity than other 
RGD-dependent integrins115. This peptide has been used to successfully inhibit tumour 
angiogenesis in the chick chorioallantoic membrane (CAM) in vivo model through inhibition of a 
fibronectin-integrin α5β1interaction116. Another non-RGD based peptide inhibitor of integrin 
α5β1called ATN-161 (Ac-PHSCN-NH2), used in conjunction with 5-FU has been shown to 
reduce the expansion of liver metastases and improve survival in mice injected intrasplenically 
with CRC cells, apparently through an anti-angiogenic effect117. ATN-161 was also capable of 
inhibiting the proliferation of breast cancer cells introduced subcutaneously into mice, as well as 
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reducing the incidence and size of metastases118. These effects appeared to be due to the anti-
angiogenic effect of the drug, as treatment with ATN-161 reduced the microvessel density within 
in vivo tumours but had no effect on the proliferation of the cancer cells in vitro118. Not all 
fibronectin receptor inhibitors are peptide-based; recently several monoclonal antibodies 
targeting this receptor have also been developed. One such agent is volociximab, a chimeric 
antibody based on the IIA1 mouse monoclonal antibody (mAb) targeting the intact α5β1 
heterodimer (but not either subunit alone)119. Volociximab or its Fab region alone are capable of 
blocking endothelial tube formation and inducing apoptosis in dividing but not senescent human 
umbilical vein endothelial cells (HUVEC) in vitro, and in preventing in vivo neovascularization 
in a cynomolgus model119. Phase I clinical trials of volociximab in several advanced, aggressive 
solid cancers have indicated the antibody is well-tolerated at doses up to30 mg/kg, with 
pharmacokinetic (PK) data indicating that the trough drug concentration consistently remained 
above the target of 150 μg/mL in patients treated with three week cycles of 20 or 30 mg/kg 
volociximab120,121. Unfortunately, a phase II study of volociximab in highly aggressive, 
oxaliplatin-resistant ovarian or peritoneal cancers was terminated early due to a lack of response 
in the first 14 patients treated122. The drug was still well-tolerated however, and the authors 
suggest that studies of volociximab therapy in earlier stage disease or as part of a combination 
therapy is still warranted122. Another mAb targeting integrin α5β1 has been developed by Pfizer, 
PF-04605412, however a recent phase I study of this antibody in solid cancers was terminated 
early due to adverse effects and insufficient drug exposure at the maximum tolerated dose123.  
1.6.5 Integrin α5 and Cell Stress 
Most efforts towards integrin α5β1 inhibitors for cancer therapy have focused on the 
angiogenic function of the heterodimer, however extensive evidence has suggested that integrin 
20 
 
α5β1 can also suppress apoptosis in response to a diverse range of stressful situations a cell may 
face. For example, many cell lines are dependent in vitro on the inclusion of serum in their 
culture media; extended deprivation of these cell lines from serum results in cell death. It was 
discovered that ectopic expression of integrin α5 in HT-29, CHO, or a normal rat small intestinal 
cell line (RIE1) protects these cells from apoptosis induced by serum withdrawal124–126. This 
effect was promoted by an adhesion to fibronectin and appeared to be mediated by the anti-
apoptotic B-cell lymphoma 2 (Bcl-2) protein125,126. Importantly, this effect appeared to require 
the full cytoplasmic domain of integrin α5, and could not be achieved with a different 
fibronectin-binding integrin, αVβ1125,126. The protective effect of integrin α5β1 expression was 
not specific to serum deprivation but could also defend the cell against treatment with various 
cytotoxic drugs, including staurosporine (a protein kinase inhibitor) and etoposide (a type II 
topoisomerase inhibitor)126. A similar effect has been observed in breast cancer cells that 
upregulate integrin α5 expression dependent on the human epidermal growth factor receptor 2 
(HER2) and hypoxia inducible factor 1 α (HIF-1α)127. The HER2 dependent upregulation of 
integrin α5 caused the cells to become more adhesive towards fibronectin and more resistant to a 
variety of insults, including serum withdrawal, hypoxia, and chemotherapy127. It seems likely 
that the protective effect of integrin α5β1, at least against chemotherapy, is mainly mediated by 
the upregulation of Bcl-2. This protein has been implicated in abrogating the cytotoxic effects of 
chemotherapy drugs like etoposide, methotrexate (MTX), or Ara-C in a wide range of cell types, 
including leukemia cells128, B-cells129, and the cervical cancer cell line HeLa130. Because of its 
ability to promote cell survival during toxic insults, it may be possible for integrin α5β1 to 
mediate an acquired CAM-DR program in CRC cells. 
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1.6.6 Integrin α5 Survival Signalling Pathways 
 Integrins are not receptor tyrosine kinases (RTKs) and do not possess intrinsic kinase 
activity themselves, but are still able to activate intracellular signalling pathways through the 
coupling of adapter proteins recruited to their cytoplasmic domains. The upregulation of Bcl-2 
by α5β1 ligation to fibronectin requires activation of the PI3K/Akt pathway126,131,132. Activation 
of the adaptor protein Src homology 2 domain containing transforming protein 1 (Shc) and a Ras 
GTPase have also been demonstrated as essential for Bcl-2 expression downstream of integrin 
α5β1 engagement and it has been suggested that these proteins are responsible for activating 
PI3K131,132. Akt activated by PI3K in turn phosphorylates the transcription factors nuclear factor 
kappa-light-chain-enhancer of activated B-cells (NF-κB), cAMP response element binding 
protein (CREB), and a forkhead box protein (FKHR)131. NF-κB and CREB are activated by Akt 
and promote transcription from the BCL2 gene, whereas phosphorylated FKHRs are inactive and 
unable to inhibit BCL2 transcription131. The interaction between fibronectin and integrin α5β1 
further results in the activation of FAK, which is also required for Bcl-2 expression125,131,132. 
FAK activation appears to act in parallel to the PI3K/Akt pathway, and integrin α5β1 receptors 
with a truncated α5 cytoplasmic domain cannot activate FAK but retain phosphorylated 
Akt125,131. Cell spreading upon adhesion to fibronectin has also been attributed to FAK125 and 
may contribute to the activation of a third pathway downstream of the fibronectin-integrin α5β1 
interaction that promotes Bcl-2 expression; activation of the Ca2+/calmodulin-dependent protein 
kinase (CaMK) IV131. Activation of CaMK IV has previously been attributed to Ca2+ release 
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from the nucleus upon cell spreading133 and in his system appears to activate NF-κB and CREB 
alongside Akt131. These signalling pathways are outlined in figure 1.4 below. 
 
Figure 1.4: Fibronectin-integrin α5β1 pro-survival signalling. 
The pro-survival pathway activated by engagement of the integrin α5β1 heterodimer with its 
ligand fibronectin, and terminating with expression of the BCL2 gene. Black arrows represent 
activating signals while red lines represent inhibitory signals.  
These images are adapted from Servier Medical Art by Servier, licensed under CC BY 3.0. 
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1.7 Rationale of the Project 
 Cancer recurrence after chemotherapy represents a major issue in CRC management as it 
often coincides with a reduced response to chemotherapy and more aggressive disease. 
Understanding the mechanisms by which resistance occurs and the changes cancer cells 
experience during the acquisition of resistance is therefore a high priority in developing better 
treatment strategies and agents. As the extracellular environment and in particular the ECM are 
strong determinants of cancer cell behaviour and survival, we chose to study the consequences of 
altered cancer cell-ECM interactions in a CRC cell line (HT-29) upon attaining a high level of 
resistance to the chemotherapy active metabolite SN-38. We have generated an SN-38-resistant 
derivative of HT-29 for this purpose (HT-29S). 
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Chapter 2: Objectives and hypothesis 
2.1 Hypothesis 
 HT-29S resistance to SN-38 is mediated by upregulation of integrin α5 and the 
subsequent activation of a fibronectin-integrin α5β1-PI3K pro-survival pathway that promotes 
the expression of BCL2.  
2.2 Objectives 
1. Identify alterations in HT-29 cell interactions with the ECM upon acquisition of SN-
38 resistance. 
2. Identify cellular receptors involved in altered ECM interactions. 
3. Determine if alterations in ECM interactions contributes to the resistant status of 
these cells, and by which mechanism.  
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Chapter 3: Methods 
3.1 Cell culture 
3.1.1 Generation of an SN-38-Resistant Cell Line  
We have previously generated a derivative of the HT-29 CRC cell line that is highly 
resistant to SN-38 through sequentially increasing exposure to the drug in culture media, as 
outlined in figure 3.1. We have named this resistant lineage “HT-29S”. Resistance in HT-29S is 
maintained by inclusion of 30 nM SN-38 in the media of stock cultures. 
 
 
 
3.1.2 Routine Passaging  
The CRC cell line HT29 and its SN-38-resistant derivative HT-29S were routinely grown 
in Nunc T25 cell culture flasks with filter caps (Thermo Scientific). Cells were cultured at 37°C 
in a humidified atmosphere of 5% CO2, in Hyclone Dulbeco’s Modified Eagle Medium (DMEM, 
Thermo Scientific) containing 4 mM L-glutamine and 4500 mg/L L-glucose, 1 mM sodium 
pyruvate, and 10% fetal bovine serum (FBS).To maintain drug resistance, HT29-S cell medium 
included 30 nM SN-38 (Sigma Aldrich). Cultures approaching confluence were passaged after 
being released by incubation for several minutes at 37°C with 1 mL TrypLE Express (Life 
Technologies). 10-15% of the resulting suspension was seeded into fresh media in a new culture 
vessel.  
Figure 3.1: Generation of the HT-29S cell line. 
Strategy for the development of the SN-38-resistant HT29-S cell line from parental HT-29 
cells. 
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3.2 Western Blot 
3.2.1 Protein Collection 
 Western blots were performed on whole cell protein lysates collected from HT29 or 
HT29-S cells using radioimmunoprecipitation assay (RIPA) buffer [table A.1]. CRC cells were 
seeded into the desired culture vessel and grown to approximately 80% confluence. Cells were 
cultured normally (see section 2.1) unless specific treatment (e.g. with PI3K inhibitors) was 
required. In those cases, inhibitor-treated cells were cultured in parallel with vehicle-control 
cultures. Upon reaching the desired confluence, medium was aspirated and the cultures were 
rinsed twice with an equal volume of sterile ice-cold phosphate-buffered saline (PBS) [table A.2] 
to remove dead cells. RIPA buffer with added HALT protease/phosphatase inhibitor cocktail 
(Thermo Fisher Scientific) was applied to the cultures (1 mL for a T75 flask or 240 μL per well 
for a 6-well plate). Cells were incubated with RIPA buffer for 30 minutes at 4°C with gentle 
agitation on a Rocker II model 260350 (Boekel Scientific). The resulting lysate was collected 
into a chilled 1.5 mL microcentrifuge tube. Complete lysis was ensured by passing the lysate 
through a 27 gauge needle with a 1 mL syringe several times. The lysate was subjected to one 
freeze-thaw cycle (-80°C to 4°C). Cell membranes were pelleted by centrifugation at 14 000 x g 
for 20 minutes at 4°C in a 5424R microcentrifuge (Eppendorf). The supernatant was collected 
and transferred to a fresh microcentrifuge tube. Protein content was determined by the Bradford 
assay (section 2.2.2). 
For some experiments, protein lysates enriched for the cytosolic fraction were used 
instead of whole cell lysates. Protein samples from the nuclear and cytosolic compartments of 
CRC cells were collected using a nuclear extraction kit (Millipore, 2900), according to the 
manufacturer’s directions. Cells were seeded and cultured in a T75 flask (Nunc) as described 
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previously, again to approximately 80% confluence. The media was then aspirated and the 
monolayer was rinsed with sterile ice-cold PBS. Cells were released by incubation with TrypLE 
for several minutes at 37°C. The resulting suspension was then passed through a 70 μm pore 
filter into a 50 mL Falcon tube (Corning). The culture vessel was rinsed twice with PBS, with 
each rinse being added to the 50 mL tube. Cells were pelleted by centrifuging the suspension at 
400 x g for 5 minutes at 4°C in an Allegra X-22R centrifuge (Beckman Coulter). The supernatant 
was discarded, and the resulting cell pellet was rinsed twice by re-suspending in 40 mL cold 
PBS. Centrifugation at 400 x g for 5 minutes at 4°C was repeated. After the final wash, the cell 
pellet was re-suspended in 500 μL cold cytoplasmic lysis buffer by gentle inversion. The cell 
suspension was incubated on ice for 15 minutes. Cells were again pelleted by centrifugation at 
400 x g for 5 minutes at 4°C. The supernatant was discarded, and the cells were re-suspended in 
1 mL of fresh cold cytoplasmic lysis buffer. Lysis of the cytoplasmic membrane was achieved by 
passing the cells through a 27 gauge needle five times with a 1 mL syringe. The final ejection 
was into a clean 1.5 mL microcentrifuge tube. The lysed cell suspension was centrifuged at 8000 
x g for 20 minutes at 4°C. The resulting supernatant, representing the cytosolic protein fraction, 
was collected into a new microcentrifuge tube and stored on ice. The resulting pellet contained 
the still-intact nuclei, which were gently re-suspended in 200 μL cold nuclear lysis buffer. 
Nuclear lysis was achieved by briefly pulsing the nuclear suspension five times with a probe 
sonicator. The lysed suspension was then incubated at 4°C with gentle agitation for 60 minutes, 
before centrifugation at 16 000 x g for 5 minutes at 4°C. The resulting supernatant contained the 
nuclear protein fraction, which was then transferred to a new 1.5 mL microcentrifuge tube and 
stored on ice. The protein concentrations of the collected nuclear and cytosolic fractions were 
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measured by the Bradford assay (section 2.2.2) before dispensing into appropriately-sized 
aliquots for long-term storage at -80°C.  
3.2.2 Bradford Assay  
The protein content of the collected protein samples was measured by the Bradford assay. 
A 96-well plate was loaded in triplicate with bovine serum albumin (BSA; Sigma Aldrich) 
standards in 20% RIPA buffer at concentrations of 0, 50, 125, 250, 375, 500, 750, and 1000 
μg/mL. Protein samples were diluted 5-10 fold in MilliQ H2O and 2-8 μL of samples were 
loaded in triplicate into adjacent wells on the same plate. At least two different volumes of each 
diluted sample was used, to improve the accuracy of the estimate. Two hundred microlitres of 
Bradford reagent (Coomassie Brilliant Blue G-250; Biorad) were added to each well and mixed 
by pipetting. Absorbance was measured at 595 nm on a M5 Spectramax spectrophotometer 
(Molecular devices). Protein concentrations were calculated from the standard curve generated 
by the known BSA standards. 
3.2.3 SDS-PAGE 
Proteins were separated based on molecular weight by sodium dodecyl sulphate (SDS) 
polyacrylamide gel electrophoresis (PAGE). Samples were prepared for SDS-PAGE by diluting 
all samples to an equal protein concentration in MilliQ H2O, NuPAGE LDS sample buffer [Life 
Technologies, table A.3] and 50 mM (final) dithiothreitol (DTT). Diluted proteins were 
denatured by heating to 70°C for 10 minutes prior to loading into a 4% stacking/8% resolving 
polyacrylamide gel [tables 6.5 and 6.6]. Electrophoresis was performed in running buffer [table 
A.4] at 110V to separate the proteins by molecular weight. Separation was monitored by the 
migration of the phenol red and SERVA blue G250 dyes from the NuPAGE LDS sample buffer.  
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3.2.4 Electroblotting 
The separated proteins were then transferred to a 0.2 μM polyvinylfluoridine (PVDF) 
membrane (Biorad) using a Trans-Blot SD Semi-dry Transfer Cell (Biorad). In preparation for 
transfer, the polyacrylamide gels containing the separated proteins were equilibrated and desalted 
in transfer buffer [table A.7] for 15 minutes prior to transferring. Extra thick blot papers (Biorad) 
and PVDF membranes were pre-wetted prior to transfer with transfer buffer and methanol 
respectively. Transfer was performed for 45 minutes at 25 volts. PVDF membranes were 
subsequently subjected to immunolabelling to determine the abundance of specific proteins in 
each sample.  
3.2.4 Immunolabelling 
To block non-specific binding of antibodies, PVDF membranes were blocked in tris-
buffered saline with tween-20 (TBS-T) [table A.8] and 5% skim milk for one hour at room 
temperature, with gentle agitation. At the end of the hour, the blocking solution was poured off 
and the membranes were rinsed once with TBS-T before applying 10 mL of primary antibody 
diluted 1:500 to 1:2000 in TBS-T 1% BSA. PVDF membranes were incubated with primary 
antibodies at 4°C overnight with gentle agitation. For very weakly expressed proteins (e.g. 
phosphorylated forms of kinases) incubation was extended to approximately 40 hours. At the end 
of the incubation period, the primary antibody solution were removed and stored at -20°C for re-
use (up to 4 times). Unbound primary antibodies were removed by washing the PVDF 
membranes 5 times for 5 minutes with TBS-T at room temperature with gentle agitation. Ten 
millilitres of species-specific horseradish peroxidase (HRP) conjugated secondary antibodies 
diluted 1:1000 to 1:5000 in TBS-T 1% BSA were then applied for one hour at room temperature, 
or overnight at 4°C for weakly expressed proteins, with gentle agitation. At the end of this 
30 
 
period, secondary antibodies were removed and stored at -20°C for re-use, and the membranes 
were again washed 5 times for 5 minutes with TBS-T at room temperature with gentle agitation, 
to remove unbound secondary antibodies. Antibody-bound proteins were detected by 
chemiluminescence generated by the HRP-conjugated secondary antibodies. The substrate for 
this reaction was a 1:1 mixture of luminol and peroxide from a Clarity Western ECL Substrate 
kit (Biorad), applied to the membrane for 5 minutes at room temperature immediately prior to 
detection of luminescence on an Imaging Station 4000 mm Pro camera (Kodak).  
Equal loading of protein samples was validated by detection of a housekeeping protein 
expected to be expressed at equal levels between different cell lines. For our purposes, 
glyceraldehyde-3 phosphate dehydrogenase (GAPDH) was used to verify equal loading. 
Subsequently to detection of the protein of interest, primary/secondary antibody complexes were 
stripped from the PVDF membrane by incubating with 7 mL of stripping buffer (Biorad) for 7 
minutes at room temperature with gentle agitation. The membranes were rinsed once with TBS-
T, and blocking with TBS-T 5% skim milk was repeated as described previously. HRP-
conjugated anti-GAPDH diluted 1:2000 to 1:10 000 in TBS-T 1% BSA were applied to the 
membranes for one hour at room temperature with gentle agitation. At the end of this period, the 
antibody solutions were removed and stored at -20°C for re-use, and membranes were washed 5 
times for 5 minutes with TBS-T at room temperature with gentle agitation. Detection of GAPDH 
expression was performed by chemiluminescence as described previously.  
3.3 Polymerase Chain Reaction 
3.3.1 RNA Extraction 
RNA extraction from adherent cell lines was performed using a GenEluteTM Total RNA 
Miniprep Kit (Sigma Aldrich). Cells were cultured in Nunc T25 flasks to approximately 70% 
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confluence in preparation of RNA collection. Beta-mercaptoethanol (Fisher) was added to the 
provided lysis solution as an inhibitor of endogenous RNase enzymes, to a final concentration of 
1%. Lysis was performed directly in culture flasks by aspiration of culture medium and addition 
of 1 mL of the prepared lysis solution. The lysate was collected and centrifuged in a GenEluteTM 
Filtration Column at 14 000 x g for 2 minutes to remove cellular debris and to shear the genomic 
DNA (gDNA). A volume of 70% ethanol equal to the lysate volume was then added to the 
supernatant to dissolve hydrophobic components, and the resulting solution was loaded into a 
GeneEluteTM Binding Column for centrifugation at 14 000 x g for 15 seconds. During this step, 
RNA within the supernatant was retained by the packed silica filter of the binding column. The 
resulting supernatant was discarded. The column was then washed with 500 μL of the provided 
Wash Solution 1 by centrifugation at 14 000 x g for 15 seconds. The binding column was 
transferred to a new collection tube and washed with 500 μL of Wash Solution 2 (provided as a 
concentrate and diluted in 100% ethanol) at 14 000 x g for 15 seconds. The filtrate was discarded 
and an additional wash with 500 μL of wash solution 2 was performed at 14 000 x g for 2 
minutes. The binding column with RNA retained within the filter was then transferred to a new 
collection tube. RNA was dissociated from the silica by applying 50 μL of the provided elution 
buffer and centrifuging the collection tube at 14 000 x g for 1 minute. Following elution, the 
RNA-containing solution was kept on ice to minimize degradation and loss of sample. RNA 
concentration was determined immediately following collection by measuring the absorbance of 
the sample at 260 nm using a NanoDrop® device. The purity was simultaneously assessed by the 
ratios of absorbance at 260 nm (RNA or DNA) to the absorbance at 280 nm (proteins) and 230 
nm (organic solvents). Ratios >1.8 were considered to be acceptably pure, however with this 
protocol ratios >2 were usually attained. RNA was stored long-term at -80°C.  
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3.3.2 Reverse Transcription 
All PCR experiments were performed in a 2-step protocol, which necessitated the 
transcription of complimentary DNA (cDNA) from RNA samples prior to amplification by PCR. 
Reverse transcription reactions were set up in a dedicated PCR hood (AirClean 600 PCR 
Workstation) to minimize the risk of introducing exogenous genetic material or nuclease 
enzymes into the mix. For each sample, 2.5 μg of RNA was reverse transcribed in 50 μL 
reactions performed in triplicate. Additionally, for each sample a mock “no-RT” reaction was 
performed by excluding the reverse transcriptase enzyme, in order to assess the contribution of 
contaminating gDNA in PCR reactions. Reactions were set-up from two master mixes. The first 
contained equal volumes of 0.5 μg/μL oligo dT (Invitrogen) as a primer for mRNA reverse 
transcription and 10 nM deoxynucleotide triphosphates (dNTP; Invitrogen). Twenty microlitres 
of the second master mix was required per reaction, and consisted of 10 μL 5X first strand buffer 
(Invitrogen), 5 μL 0.1M DTT (Invitrogen), 2.5 μL recombinant ribonuclease inhibitor (RNase 
out; Life Technologies), and 2.5 μL Moloney murine leukemia virus (M-MLV; Life 
Technologies) reverse transcriptase. For the no-RT controls, a separate master mix 2 was 
prepared with the M-MLV reverse transcriptase replaced by diethylpyrocarbonate (DEPC; Life 
Technologies)-treated H2O. A volume of each sample containing 2.5 μg RNA was added to a 
PCR reaction tube diluted in DEPC-treated H2O to a final volume of 25 μL. Five microlitres of 
master mix 1 was then added to the tube. The reaction tubes were capped and transferred to a 
Techne Genius Thermocycler® to be incubated at 65°C for 5 min. The tubes were then chilled 
on ice for 15 seconds before adding 20 μL of master mix 2. Tubes were returned to the 
thermocycler and run at 37°C for 50 minutes followed by 70°C for 15 minutes. The final reaction 
contained cDNA at a concentration of 50 ng/μL RNA-equivalents, and was stored at -80°C.  
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3.3.3 Primer Design 
 Many of the primer pairs used to perform the polymerase chain reaction (PCR) 
experiments described here were newly designed. Primer design was assisted through the use of 
several openly-available online resources, including PrimerBLAST from the National Center for 
Biotechnology Information (NCBI), OligoAnalyzer from Integrated DNA Technologies (IDT), 
and in silico evaluations from RTPrimerDB. Primer pairs intended for use in quantitative reverse 
transcription PCR (qRT-PCR) formats were designed according to a very stringent set of 
characteristics to ensure high-efficiency amplification of target sequences, based on 
recommendations from commercial suppliers of qPCR reagents and equipment134–136. The 
specifications used to guide the design of primer pairs are listed in table A.16. All primers were 
ordered from Life Technologies. 
3.3.4 Endpoint PCR 
To minimize the risk of contamination with exogenous genetic material or nuclease 
enzymes, all PCR reactions (endpoint and real-time) were set-up in a dedicated PCR hood 
(AirClean 600 PCR Workstation). For both endpoint and qRT-PCR reactions, a master mix was 
prepared for each pair of primers in nuclease-free 1.5 mL polypropylene tubes. For endpoint 
PCR reactions, master mixes consisted of 9.5 μL nuclease-free H2O, 0.5 μL 10 μM each of 
forward and reverse primers (final concentration of 200 nM each), and 12.5 μL GoTaq Green 
Master Mix (Promega, contains Taq DNA polymerase, dNTPs, MgCl2, reaction buffers, and 
loading dyes) per reaction. 23 μL of master mix was loaded into PCR reaction tubes for each 
sample. Each reaction was then loaded with 2 μL of sample cDNA (equivalent to 100 ng of total 
RNA). No template control (NTC) reactions were also performed using 2 μL of nuclease-free H-
2O in place of cDNA. The reaction tubes were then sealed and transferred to a Techne Genius 
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Thermocycler® to be run under the following cycling conditions: 94°C for 75s (initial denature) 
followed by 36 cycles of 94°C for 45s (denaturation), 65°C at 45s (annealing), and 72°C for 60s 
(extension), finishing with a 10 min hold at 72°C (final extension).  
To visualize reaction products, 5 μL of each reaction was loaded into a 1% agarose gel 
containing 0.2 μg/mL ethidium bromide (EtBr). Electrophoresis was performed at 94 volts for 30 
min, with progress monitored by the loading dyes present in the GoTaq master mix. Upon 
completion, gels were imaged on an AlphaImager HP gel imaging system (Alpha Innotech) for 
EtBr fluorescence stimulated by ultraviolet light. 
3.3.5 qRT-PCR 
SYBR-green based chemistry was used to quantitatively measure gene expression by 
qRT-PCR. However, prior to performing a qPCR reaction, all primer pairs to be used were 
validated for the production of a single amplicon of the correct length by endpoint PCR, as 
described in section 3.3.4. Similar to endpoint PCR experiments, qRT-PCR reactions were set-up 
in a dedicated PCR hood (AirClean 600 PCR Workstation) by preparing a master mix for each 
set of primers. Each master mix was composed of 12.5 μL 2X Brilliant II SYBR green master 
mix (Agilent; used for BCL2, ITGA5, and ZEB2) or 12.5 μL 2X GoTaq qPCR master mix 
(Promega; used for JUP, SNAI1, SNAI2, TJP1, TWIST1, VIM, and ZEB1), 0.5 μL each of 10 μM 
forward and reverse primers (final concentration of 200 nM), 0.25 μL reference dye (Rox for the 
Agilent master mix, CXR for the Promega master mix), and 6.25 μL nuclease-free H2O 
(Promega) per qRT-PCR reaction to be performed. Reactions were performed in a 96-well semi-
skirted qRT-PCR plates (Thermo Scientific) with 20 μL of master mix and 5 μL of cDNA 
diluted tenfold in nuclease-free H2O (25 ng RNA-equivalents) per well. Each sample was 
assayed in triplicate and with no-RT mock reactions as a control against fluorescence signals 
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from contaminating exogenous or unsheared gDNA. Reactions were mixed by pipetting and 
sealed with a clear adhesive plate seals (Thermo Scientific). The sealed plate was then placed in 
a StepOnePlus Real-Time PCR System (Applied Biosystems) and run under the manufacturer-
recommended cycling conditions: hot-start at 95°C for 2 minutes (Promega kit) or 10 minutes 
(Agilent kit) followed by 40 cycles of 95°C for 15 seconds (Promega kit) or 30 seconds (Agilent 
kit) (melting) then 60°C for 60 seconds (annealing and extension), with SYBR fluorescence read 
between every cycle. Immediately after all 40 cycles were completed, a melt curve was 
performed. StepOnePlus’s associated software used the melt curve data to generate a derivative 
fluorescence versus temperature plot, which was used to confirm the absence of multiple 
amplification products or primer-dimer contributions to SYBR fluorescence.  
Amplification data from the qRT-PCR reaction was exported from the StepOnePlus 
software into a Microsoft Excel file for further analysis. Raw, baseline-unadjusted fluorescence 
data was analyzed for reaction efficiency and failure to reach the plateau phase using the 
LinRegPCR software, validated and described elsewhere137,138. For each reaction, a relative 
initial mRNA concentration (N0) value (in arbitrary fluorescence units; AFU) was determined by 
LinRegPCR using the equation in figure 3.2. 
NO =  
NCq
Eff Cq
⁄  
Figure 3.2: Calculation of initial mRNA abundance. 
The initial abundance of a particular mRNA species was estimated from the fluorescence at 
the quantification cycle (NCq), the reaction efficiency (Eff), and the quantification cycle (Cq) 
number. This analysis was performed with the LinRegPCR software137,138. 
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A threshold fluorescence value significantly above the fluorescence baseline was 
determined by LinRegPCR for each amplicon group, and the cycle at which a particular reaction 
achieved this fluorescence threshold was the Cq for that reaction. The fluorescence at Cq was the 
NCq, expressed in arbitrary fluorescence units (AFU). The efficiency of each individual reaction 
was determined by LinRegPCR through linear regression of the log fluorescence versus cycle 
number during the exponential phase of the reaction. A mean efficiency (Eff) was calculated for 
each amplicon group and used in the determination of NO. 
3.4 Immunofluorescence 
3.4.1 Monolayer Immunofluorescence  
Expression and localization of proteins within CRC cells was performed by 
immunofluorescence on cells grown on Nunc Lab Tek II chamberslides (Thermo Scientific). 
Chamber slides were prepared a day in advance of seeding by applying 300 μL of 10 μg/mL 
poly-L-lysine (PLL; Sigma Aldrich) for 10 minutes at 37°C. PLL was then aspirated from the 
wells and chamber slides were left to dry overnight at 37°C. The following day, CRC cells were 
seeded into the wells of the chamber slide in 400 μL DMEM 10% FBS and cultured normally. 
Media in HT29-S cell wells additionally included 30 nM SN-38 to maintain selective pressure 
for the drug-resistant population. Because of the slightly different growth rates of the HT29 and 
HT29-S cell lines, the initial seeding density was slightly higher for HT29-S; each well was 
seeded with 16 000 HT29 cells or 20 000 HT29-S cells. Upon attaining ~75-85% confluency 
(approximately 5 days), media were aspirated and cell monolayers were washed with cold PBS 
containing Ca2+ and Mg2+. The monolayers were then fixed using one of two fixation methods 
depending upon the primary antibody. The first method involved applying methanol (MeOH) 
pre-chilled to -20°C to cells and allowing fixation to occur over a 15 minute period on ice. 
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Alternatively, cells were fixed using 200 μL of pre-warmed (to 37°C), freshly-prepared 3.7% 
paraformaldehyde (PFA; Sigma Aldrich), [table A.9] for 15 minutes at 37°C. At the end of the 
PFA incubation period, monolayers were washed once with PBS containing Ca2+ and Mg2+ 
before permeabilization of the cells with 200 μL of PBS containing Ca2+ and Mg2+ [table A.10], 
1% Triton X-100 (Fisher) for 5 minutes at room temperature.  
After the cells were fixed, 200 μL of 5% FBS in PBS containing Ca2+ and Mg2+ was 
applied to each well for 1 hour at room temperature, in order to block non-specific binding of 
primary antibodies. The blocking solution was then removed and 200 μL of primary antibody 
diluted in PBS containing Ca2+ and Mg2+ was applied to each well overnight at 4°C. At the end 
of this incubation period, primary antibody dilutions were removed and wells were washed 3 x 5 
minutes with PBS containing Ca2+ and Mg2+. Alexafluor fluorophore-conjugated secondary 
antibodies (see table A.14) directed against the host species of the primary antibodies, diluted in 
PBS containing Ca2+ and Mg2+ (2 μg/mL), were then applied to each well for one hour at room 
temperature. The secondary antibody solutions were removed and each well was again washed 3 
x 5 minutes with PBS containing Ca2+ and Mg2+. The plastic chambers were then carefully 
removed using the wedge tool provided by manufacturer. One drop of Fluoroshield aqueous gel 
mountant containing 1 μg/mL 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI; Abcam) 
was applied to each well to counterstain cell nuclei and to mount a cover slip. Mountant was 
allowed to dry overnight at room temperature, protected from light. Fluorescence was detected 
on a Leica DM2000 light microscope with an ebq100 power supply. Images were taken using the 
QCapture Pro 5 software and Micropublisher 5.0 RTV camera (both from QImaging). 
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3.4.2 Spheroid Immunofluorescence 
Spheroids were grown by seeding cells in 40 μL DMEM 10% FBS (with 30 nM SN-38 
for HT-29S) into each well of a 96-well hanging drop plate. The standard seeding density was 
200 cells per well, however this was at times varied to yield spheroids of different sizes. Each 
cell line was seeded onto a separate plate to ease the collection of spheroids. Sterile MilliQ H2O 
was loaded into the outer reservoir of the plates to maintain a high humidity within the plate, and 
the entire plate was covered in saran wrap to maintain humidity. Plates were cultured at 37°C, 
5% CO2 for 4-5 days. Each well yielded a single spheroid, and because a precise number of 
spheroids was not required for immunostaining, all of the spheroids from a single plate were 
collected simultaneously. The plates were carefully removed from the incubator, unwrapped, and 
the middle section of the plate (containing the spheroids) was carefully removed. The lid of the 
hanging-drop plate was inverted and held underneath the middle section. These sections were 
raised several inches above the biosafety cabinet surface and swiftly brought down to knock all 
of the spheroids out of the wells and onto the lid underneath. The lid was washed twice with 5 
mL of cold sterile PBS, collecting both washes into a clean and sterile labeled 50 mL centrifuge 
tube. The tubes were allowed to chill on ice while spheroids settled to the bottom. Spheroids are 
large enough to be seen with the naked eye, so once it was apparent that all spheroids had settled, 
PBS was carefully poured off. The spheroids were gently re-suspended in cold PBS containing 
Ca2+ and Mg2+ (non-sterile) and transferred to a 1.5 mL microcentrifuge tube. 
Immunofluorescence was performed on CRC spheroids using a modified approach from 
the method described in section 2.4.1. Fixation was performed with a volume of 500 μL of 3.7 
PFA or cold MeOH in microcentrifuge tubes. All washes were performed with 1 mL of cold PBS 
containing Ca2+ and Mg2+. Antibody dilutions and blocking solution was applied in 200 μL 
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volumes. To remove washes or other solutions, microcentrifuge tubes were briefly pulsed on an 
SD 110 benchtop microcentrifuge (BioLynx) to pellet the spheroids, and the supernatant was 
poured off. At the end of the staining procedure, spheroids were re-suspended in 20-25 μL of 
Fluoroshield aqueous gel mountant containing 1 μg/mL DAPI, applied to a glass slide, and 
covered with a 22 mm circular glass coverslip. Imaging was performed as described in section 
2.4.1. 
3.5 Adhesion Assay 
 Twenty-four well plates were coated with 500 μL per well of 5 μg/mL bovine plasma 
fibronectin (Sigma Aldrich) in PBS overnight at 4°C. At the end of this period, the fibronectin 
solution was aspirated from the wells and 500 μL of serum-free DMEM containing 2% BSA was 
applied to each well for 10 minutes at room temperature, to block non-specific interactions. HT-
29 and HT-29S cells cultured in a T25 flask were solubilized by incubation with 1 mL TrypLE. 
These cells were collected into 5 mL DMEM 10% FBS to inactivate the TrypLE enzyme, and 
spun down at 400 x g for 3 minutes at 4°C on an Allegra X-22R Centrifuge (Beckman Coulter). 
To remove serum, cells were washed twice by resuspension in 10 mL cold PBS, spinning down 
at 400 x g for 3 minutes at 4°C after each wash. After the second wash, cells were re-suspended 
in 5mL serum-free DMEM, and 500 μL of this suspension was diluted in PBS to a final volume 
of 10 mL. This dilute suspension of cells was counted on a Multisizer 4 Coulter Counter 
(Beckman Coulter) to obtain the concentration of cells in the original suspension. Both cell lines 
were diluted to a concentration of 100 000 cells/mL in serum-free DMEM. This suspension was 
aliquoted into two clean microcentrifuge tubes for each cell line. Glycine-arginine-glycine-
aspartic acid-serine-proline (GRGDSP) or glycine-arginine-alanine-aspartic acid-serine-proline 
(GRADSP) (Millipore) peptides at a concentration of 10 mg/mL in MilliQ H2O were diluted into 
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the microcentrifuge tubes to a final concentration of 100 μg/mL. Five-hundred microliters of 
each suspension was added, in triplicate, to the fibronectin-coated 24-well plate. The plate was 
gently shaken to ensure even distribution of the cells throughout each well. The plate was then 
returned to the 37°C incubator for approximately 2 hours, during which time cells were allowed 
to adhere to the immobilized fibronectin. At the 
end of this period, the plate was washed twice by 
gently inverting into cold PBS containing Ca2+ 
and Mg2+ for 10 minutes to remove non-adhered 
cells. The cells that remained adhered after 
washing were fixed and stained with hematoxylin 
and eosin Y (H&E), following the directions of 
section 2.6.  
 Following H&E staining, each well was 
divided into 9 equal according to the layout shown 
in figure 3.3, and an image was taken from the centres of each of those sections at 100X 
magnification on an Eclipse TE200 inverted microscope (Nikon). This very systematic approach 
to image acquisition was employed to minimize bias in data collection, as dispersion of adhered 
cells throughout a well was often highly variable. Cells within each field were counted using 
ImageJ’s cell counter plugin.  
3.6 Hematoxylin and Eosin Y Staining 
 A regressive H&E staining method using Harris’ Hematoxylin (Sigma Aldrich) and 1% 
eosin Y (Sigma Aldrich) was employed to stain adherent CRC cells. After the final wash of the 
adhesion assay, the remaining cells were fixed in 500 μL of 3.7% PFA overnight at room 
 
Figure 3.3: Adhesion assay well 
divisions. 
Each well on an adhesion assay plate was 
divided into 9 separate fields following 
this layout. 
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temperature. The PFA was then aspirated and the plate was rinsed well with running tap water. 
500 μL of Harris’ Hematoxylin was applied each well for approximately 10 minutes at room 
temperature. The hematoxylin was recovered for reuse, and the plate was washed well with 
running tap water. Non-nuclear background staining by hematoxylin was removed by using a 
pipette to repeatedly apply and aspirated 500 μL of acid/alcohol [table A.11] to each well in turn 
for 5-10 seconds. Scot’s Tap Water [table A.12] was then applied to every well at a volume at 
500 μL until the cells were fully blue (approximately 5 minutes). Counterstaining was then 
performed by applying 500 μL of eosin Y to each well for approximately 10 minutes. Eosin Y 
was recovered for reuse, and each well was rinsed well with running tap water. Cells were then 
dehydrated through progressive rinses with 70%, 95%, and 2 x 100% ethanol. To obtain high-
quality images of adhered cell morphology, wells were rinsed several times with soft tap water to 
remove dust before 500 μL of soft tap water was applied to rehydrate the fixed and stained cells.  
3.7 Cellular Proliferation (MTT) Assay  
  The size of the viable cell population after challenge with chemical or environmental 
stressors was measured by the conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) by mitochondrial reductase enzymes to the 5-(4,5-
dimethylthiazol-2-yl)-1,3-diphenylformazan (formazan). Cells were seeded in DMEM 10% FBS 
at the desired density in 96-well plates and incubated at 37°C, 5% CO2 overnight. After allowing 
adhesion to the tissue culture plate, cells were challenged as desired (e.g. with drugs or serum 
deprivation) and cultured for at 37°C, 5% CO2 for an assay-specific incubation period. At the 
end of this period, medium was aspirated and 100 μL of 0.5 mg/mL MTT in PBS containing 
Ca2+ and Mg2+ was applied. Cellular morphology was checked at this time. The plate was 
incubated with the MTT reagent at 37°C for 2-4 hours, during which time MTT was reduced to 
42 
 
formazan. The MTT reagent was then aspirated and the formazan crystals were dissolved in 100 
μL of dimethyl sulfoxide (DMSO) for 15 minutes at 37°C. At the end of the dissolution period, 
the samples were mixed by gentle pipetting and the absorbance was measured at 540 nm on a 
SpectraMax M5 Plate Reader. Background absorbance from blank control wells were performed 
alongside experimental wells to account for the background absorbance. 
3.9 Statistical Analysis 
Analysis of the collected data was performed using GraphPad Prism 5 software. 
Comparisons for statistically significant differences between the HT-29 and HT-29S cell lines 
used the Mann-Whitney test, with p < 0.05 chosen as a threshold for statistically significant 
differences. An unpaired t-test was used instead of the Mann-Whitney test for analyzing the CRC 
cell nuclei diameter because of the large sample sizes in this assay. Adhesion assay data was 
analyzed by two-way analysis of variation (ANOVA), where peptide treatment and cell line were 
the variables. Statistically significant differences were determined by a Bonferroni post-test, with 
a threshold of p < 0.05 deemed to be significant. Non-linear regression and an extra sum of 
squares F test was performed on dose-response data to test for differences in IC50 values 
between treatment groups. A threshold of p < 0.05 was again chosen for statistical significance. 
Experiments were performed with a minimum of three independent biological replicates.  
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Chapter 4: Results 
4.1 Morphology of an SN-38-Resistant HT-29 Derivative 
Several distinct changes in cellular morphology and behaviour were apparent in HT-29S 
cells. First of all, the typical flat, cobblestone morphology of HT-29 cells grown in 2D culture 
conditions is disrupted in HT-29S cells Even at low confluency, HT-29S cells will begin 
growing over top of each other, suggesting a loss of contact inhibition. With prolonged culture 
periods, these areas continue to grow upwards away from the plastic culture surface, forming 
long, firmly attached stalks of HT-29S cells called “nodules” [fig. 4.1 A)]. Immunofluorescence 
experiments revealed another interesting difference between these cell lines; the nuclei of HT-
29S cells are significantly larger and more heterogeneous in diameter than those of HT-29 [fig. 
4.1 B) and C), table 4.1]. 
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Figure 4.1: Morphological differences between HT-29 and HT29S. 
A) HT-29 and HT-29S cells were cultured in 2D culture conditions in T25 flasks (Nunc). 
Images were taken on a Motic AE21 inverted microscope. 
B) HT-29 and HT-29S were seeded, cultured, and fixed on Nunc chamber slides prior to 
staining DAPI and mounting. Nuclei were measured at their widest diameter by two 
blinded observers using the Q-Capture Pro7 software (QImaging). The presented 
results represent nuclei from six independent experiments. 
*** p < 0.0001 by the unpaired t-test. 
C) Sample images of nuclei from HT-29 and HT-29S used for the measurements taken in 
B). Nuclei are have been stained with DAPI. Images were taken on a Leica DM2000 
fluorescent microscope using the Q-Capture Pro 7 software (QImaging) at 400X 
magnification. 
 
 
  
 HT-29 HT-29S 
n 451 386 
Mean Diameter (μm) 15.50 19.28 
Median Diameter (μm) 15.71 18.93 
Standard Deviation (μm) 2.189 3.831 
Minimum (μm) 8.560 10.86 
Maximum (μm) 23.76 32.02 
 
Table 4.1: Cell nuclei measurement data 
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4.2 HT-29S spheroids have an increased ability to form fibronectin matrices 
 We wished to determine the contribution of the tumour microenvironment ECM to the 
phenotypic changes that occur in HT-29S cells in culture upon acquisition of SN-38 resistance. 
We therefore performed immunofluorescence experiments against various ECM proteins on HT-
29 and HT-29S cells. In a pilot experiment using 2D cultures of our CRC cell lines, we noticed 
that HT-29S nodules showed stronger fibronectin staining within their nodules as opposed to the 
surrounding monolayer (data not shown). We reasoned that the ECM may form a scaffold for the 
formation of the nodules, and therefore that the ECM may be more important in 3D conditions. 
Further immunofluorescence experiments were therefore performed on 3D CRC spheroids 
generated using the hanging drop culture method. Immunofluorescence experiments of these 
spheroids revealed HT-29 spheroids to be nearly absent of fibronectin staining [fig. 4.2 A)] HT-
29S spheroids on the other hand showed a stronger, granular staining pattern for the ECM 
protein [fig. 4.2 A)]. In the middle of very large HT-29S spheroids, this granular staining pattern 
gave way to intense, fibrous staining for fibronectin [fig. 4.2 B)]. As can be seen in figure 4.2 B) 
using brightfield illumination, the area of the HT-29S spheroids from which the intense fibrous 
staining is produced is absent of any foreign material or apparent defect of the spheroid that 
could potentially cause artefactual fluorescence. Thus, it appears that these areas represent 
genuine fibronectin matrix formation.  
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HT-29: Fibronectin HT-29S: Fibronectin 
Figure 4.2: Fibronectin matrix formation in CRC spheroids. 
HT-29 and HT-29S spheroids were grown by seeding CRC cells in hanging drop plates and 
culturing for several days at 37°C, 5% CO2. Spheroids were collected and immunostained for 
fibronectin expression.  
A) Fibronectin expression and matrix formation in comparably sized HT-29 and HT-29S 
spheroids. 
B) Large HT-29S spheroid showing a fibrous staining pattern for fibronectin (left) and the 
corresponding brightfield image.  
All images were taken on a Leica DM2000 microscope and QImaging Micropublisher 5.0 
RTV camera using the QCapture Pro 7 Software (QImaging). Images are representative of 
four independent immunofluorescence experiments. 
A) 
 
B) 
 
HT-29S: Fibronectin HT-29S: Brightfield 
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4.3 HT-29S cells have a strongly increased capacity for adhesion to immobilized 
fibronectin.  
We wished to determine if the change in fibronectin deposition was related to a change in 
the ability of HT-29S to interact with the ECM glycoprotein. Adhesion assays were therefore 
performed to characterize the interaction between our CRC cells and immobilized fibronectin. 
CRC cells suspended in serum-free DMEM were allowed to adhere to fibronectin coated to a 
six-well plate over a 2-h period. Serum-free media was used in these experiments because 
fibronectin is abundant as a soluble dimer in serum and therefore could have interfered with the 
assay. A soluble GRGDSP peptide treatment group was included in the assay to test the RGD-
dependence of any interaction between the CRC cells and fibronectin. The inactive peptide 
GRADSP was used as a control. At the end of the adhesion period, non-adhered or loosely-
adhered cells were washed away and the remaining tightly-bound cells were fixed, stained, and 
counted. HT-29 cells showed almost no degree of adhesion in any of the conditions tested [fig. 
3.4 A)]. In comparison, HT-29S cells showed a variable but higher degree of adhesion in the 
control and GRADSP-treated groups [fig. 4.3 A)]. Two-way ANOVA indicated that both the cell 
line (p < 0.01) and peptide treatments (p < 0.05) significantly influenced the number of adhered 
cells. Importantly, the inclusion of GRGDSP with HT-29S was sufficient to completely abolish 
adhesion to immobilized fibronectin, suggesting the interaction is RGD-dependent [fig. 4.3 A)]. 
The difference in adhesion between HT-29S cells treated with the GRGDSP and GRADSP 
peptides was statistically significant, as was the difference between HT-29 and HT-29S cells 
treated with the negative control peptide (p < 0.01).  
There was also a significant difference in the morphology of adhered cells between HT-
29 and HT-29S in this assay. The very small number of HT-29 cells that were retained at the end 
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of the adhesion period appeared small and spherical [fig. 4.3 B)], greatly resembling a cell that 
has been detached from its substratum. This suggests that these rare cells represent low affinity 
interactions with the plastic of fibronectin that were insufficient to trigger spreading HT-29S 
cells on the other hand appeared to have flattened out and produced long cellular extensions in 
the control and GRADSP-treated groups [fig. 4.3 B)]. This spreading morphology was lost upon 
treatment with the GRGDSP peptide; the few adhered HT-29S cells under these conditions 
appeared “rounded-up” and greatly resembled their HT-29 counterparts [fig. 4.3 B)].   
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Figure 4.3: RGD-dependent adhesion of HT-29 and HT-29S cells to immobilized 
fibronectin. 
A)   HT-29 and HT-29S cells suspended in serum-free DMEM were allowed to adhere to 
fibronectin coated onto a six-well plate over a period of two hours. Non-adhered cells 
were washed away and the remaining adhered cells were fixed with 3.7% PFA and 
stained with H&E. Nine images were taken per well at 100X magnification and the 
number of adhered cells per field was counted using ImageJ. The results presented 
here represent four independent experiments. Differences in adhesion between HT-29 
and HT-29S were assessed by two-way ANOVA (Bonferroni post-test). ** p < 0.01.   
B)  Representative images showing the morphology of adhered and stained HT29 and 
HT-29S cells, taken at 200X.  
All images were taken on a Nikon Eclipse TE200 inverted microscope and a QImaging 
Micropublisher 5.0 RTV camera using the QCapture Pro 7 Software (QImaging).   
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4.4 Expression of the integrin α5 subunit is strongly increased in SN-38-resistant 
HT-29 cells.  
 The observation of increased fibronectin matrix assembly in HT-29S spheroids as well as 
the ability of the ability of the resistant cells to adhere to immobilized fibronectin in an RGD-
dependent manner led us to explore the expression of various integrin subunits in the HT-29 and 
HT-29S cell lines. We focused on integrins which are known to dimerize to form fibronectin 
receptors, and were especially interested in those that do so in an-RGD dependent manner, such 
as integrin α5β1 and αVβ3. Integrin subunit expression was investigated at the protein level by 
SDS-PAGE and immunoblotting. The expression of integrin subunits α9, αV, β1, β3, and β5 
were all strongly reduced in HT-29S compared to HT-29 protein lysates [fig. 4.4 A)]. The 
reduction in β1 expression is striking, as this is a common and major subunit that forms 
heterodimers with many different α integrins. Extensive exposure of integrin β1 immunoblots 
reveals a faint signal in HT-29S [fig. 4.4 B)]. It therefore appears that integrin β1 expression is 
strongly reduced but not entirely absent in the drug-resistant cell line, and that dimers containing 
β1 may nevertheless exist. Integrin α6 also appeared mildly reduced, but more interestingly 
shifted to a slightly lower molecular weight in HT-29S [fig. 4.4 A)]. In contrast to the trend of 
integrin downregulation in HT-29S, the expression of integrin subunit α5 was dramatically 
increased [fig. 4.4 A)].  
  To determine whether the change in integrin α5 expression was a result of increased 
expression of its gene ITGA5 expression or reduced degradation of the protein, qRT-PCR was 
performed. The sequences and other relevant characteristics of the primer pairs used in these 
experiments are presented in table 6.15. Figure 4.4 C) presents the estimated initial abundance 
(N0) of ITGA5 cDNA after normalization for reaction efficiency and loading using ribosomal 
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protein L27 (RPL27) as a reference gene. ITGA5 mRNA was over 1500 times more abundant in 
HT-29S than HT-29, suggesting a very strong increase in transcription from the ITGA5 gene, or 
possibly a dramatic increase in the half-life of the mRNA [fig. 4.4 C)].  
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Figure 4.4: Integrin subunit protein and gene-level expression by immunoblotting and 
real-time PCR. 
A)  HT-29 and HT-29S cytosolic protein fractions were immunoblotted for expression of 
individual integrin subunits. The primary and secondary antibodies used are recorded in 
tables 6.13 and 6.14. GAPDH was used as a loading control. Results shown are 
representative of three independent samples. 
B) Integrin β1 immunoblot from A), exposed past the point of saturation. 
C)  The expression of the ITGA5 gene was measured using SYBR green based qRT-PCR. 
Reactions were performed in triplicate on 25 ng (RNA equivalent) of reverse transcribed 
cDNA on a StepOnePlus Real-Time PCR system (Applied Biosystems). The primers 
used for these experiments are listed in table 6.15. Samples were normalized for loading 
differences against the housekeeping gene RPL27. Data is presented as the mean + SEM 
from four independent samples. Statistically significant differences in expression were 
determined by the Mann-Whitney test. * p < 0.05 
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The localization of an integrin heterodimer within the cell can reveal a great deal about 
the receptor; they may be clustered into points of contact with the ECM called focal adhesions, 
or internalized into intracellular vesicles (reviewed in 139). We therefore performed 
immunofluorescence experiments to determine the localization of integrin α5 within HT-29 and 
HT-29S cells, and to confirm the change in expression observed by western blot and qRT-PCR. 
Rabbit isotype antibodies were used to establish exposure limits as a control against auto-
fluorescence and background staining. Similar to the western blot results, integrin α5 appeared to 
be more highly expressed in the SN-38-resistant cell line. [fig. 4.5 A)].  
 The subcellular localization of positive integrin α5 staining was also significantly altered 
in HT-29 versus HT-29S cells. The parental cells had a consistent low level of fluorescence 
throughout the cytoplasm, not co-localizing with any apparent structures and showing no 
variation between cells within a colony [fig. 4.5 A)]. This suggests that a small amount of 
integrin α5 may be expressed in HT-29 but is not functionally active or associated with the ECM. 
The HT-29S cells stained for integrin α5 did not have such a uniform staining; colonies appeared 
to be surrounded by a thin but intense margin of integrin α5 [fig. 4.5 A)]. At high magnification, 
many of these margins have the appearance of thin fibrous strands [fig. 4.5 B)], which may 
reflect integrin α5β1 engagement with an ECM matrix, analogous to the fibrous strands of 
fibronectin observed in HT-29S spheroids [fig. 4.2 B)]. 
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Figure 4.5: Intracellular expression and localization of integrin α5 in HT-29 and HT-29S 
cells. 
A)  HT-29 and HT-29S cells were seeded and cultured on 8-well chamber slides (Nunc), 
fixed with cold methanol, and immunostained for integrin α5 or integrin β1 expression 
and intracellular localization. Nuclei were counterstained with DAPI. Control stains with 
anti-rabbit IgG were performed in parallel as a negative control against nonspecific 
binding and cellular auto-fluorescence.  
B)  Fibrous staining pattern of integrin α5 at the surface of HT-29S cells, indicated by the 
white arrows. Nuclei were counterstained with DAPI. 
All images were taken on a Leica DM2000 microscope and QImaging Micropublisher 5.0 
RTV camera using the QCapture Pro 7 Software (QImaging). Images are representative of 
three independent immunofluorescence experiments. 
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4.5 HT-29S cells are resistant to extended serum deprivation 
 Integrin α5 is known to form only a single heterodimer, which is the α5β1 receptor140. As 
integrins only function as heterodimers and not as solitary subunits, and because the expression 
of integrin β1 is strongly reduced in HT-29S, the upregulation of the integrin α5 subunit is 
insufficient evidence to prove an increased expression of the functional α5β1 fibronectin 
receptor. Furthermore, the inside-out regulation of integrin activity discussed in section 1.5.3 
suggests that even if the expression of the fibronectin receptor at the cell surface is increased, it 
may not be functionally more active. We therefore sought to test the level of functional activity 
of integrin α5β1 in HT-29S cells. Previous work by the labs of Erkki Ruoslahtti and Rudolph 
Juliano have demonstrated that ectopic expression of integrin α5 can render cells resistant to 
conditions of serum starvation, including in the HT-29 CRC cell line124,125. We therefore chose to 
use this trait as a marker for active integrin α5β1 signaling by depriving HT-29 and HT-29S of 
serum for 72 hours. At the end of this period, we performed the MTT assay to measure cellular 
viability. HT-29 and HT-29S cells cultured in serum-containing medium were used as a positive 
control, and were defined as “100% viable”. As expected, HT-29 cells are highly sensitive to 
serum withdrawal; by the end of the 72 hour period, serum starved HT-29 cell viability was 
reduced to approximately 20% of control [fig. 4.6 A)]. In contrast, serum-starved HT-29S cells 
showed a very moderate reduction in viability, at approximately 70% of control. This difference 
in serum-deprivation resistance was statistically significant (p < 0.05). HT-29S is enhanced in its 
ability to survive and proliferate under serum-free conditions, consistent with activation of a 
fibronectin-integrin α5β1 pro-survival pathway.  
 We were also able to observe a significant difference in the morphology of HT-29 and 
HT-29S cells in response to serum deprivation. When cultured in media containing serum, both 
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HT-29 and HT-29S cells in short term culture have a “cobblestone” morphology characteristic of 
epithelial cell monolayers, as can be observed in figure 4.6 B). HT-29S retains this appearance 
under serum-free conditions; there was no obvious differences in cellular morphology at the end 
of the treatment period between the serum-starved and control HT-29S cells. The only notable 
feature was a mild reduction in confluency in the serum-starved HT-29S wells, which fits with 
the observed decrease in viability measured by MTT. There was however a significant change in 
the morphology of HT-29 cells that had been subjected to serum deprivation. Not only were 
there far fewer cells within these wells, but most of the cells that were present had lost the 
cobblestone appearance of healthy epithelial cells and instead appeared more spherical.  
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  Figure 4.6: Effect of serum deprivation on HT-29 and HT-29S cells. 
A)  HT-29 and HT-29S cells were seeded into the wells of a 96-well plate in triplicate for 
each treatment group. Cells were cultured in DMEM 10% FBS at 37°C, 5% CO2 for 72 
hours. Media was then switched to fresh DMEM 10% FBS or serum-free DMEM and the 
cells were cultured for a further 72 hours. At the end of this period, an MTT assay was 
performed to assess cellular viability. Cells cultured with serum were considered 100% 
viable. The results shown represent four independent experiments. The relative viabilities 
of serum-starved HT-29 versus HT-29S cells were compared by a Mann-Whitney test.  
* p < 0.05. 
B)  Representative images of control and serum-starved HT-29 and HT-29S cells at the end 
of the 72-hour serum deprivation period. All images were taken on a Nikon Eclipse 
TE200 inverted microscope and QImaging Micropublisher 5.0 RTV camera using the 
QCapture Pro 7 Software (QImaging).   
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4.6 Akt is constitutively activated in HT-29S cells 
The pro-survival pathway activated by integrin α5β1 binding to fibronectin involves 
activation of a PI3K/Akt signalling pathway, as outlined in figure 1.4. We therefore assessed the 
degree of activation of Akt by western blot analysis for phosphorylation of Akt at two amino 
acid residues critical for its activity; serine 473 and threonine 308. Interestingly and 
unexpectedly, a decrease in the total Akt expression was also consistently observed in HT-29S 
compared to the parental cells, as can be seen in figure 4.7. Despite this reduced expression 
however, there was a clear increase in the phosphorylation of Akt at both the serine 473 and 
threonine 308 residues [fig. 4.7]. Adding weight to the results of the serum deprivation assays, 
this suggests that a fibronectin-integrin α5β1 signaling program is active in HT-29S but not HT-
29 cells.  
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Figure 4.7: Akt activation in CRC cells. 
Akt phosphorylation at Ser473 and Thr308 was assessed in HT-29 and HT-29S cell lysates by 
western blot. The primary and secondary antibodies used in these experiments are recorded in 
tables 6.13 and 6.14. GAPDH expression was used as a loading control, and is shown below 
each blot. The results shown are representative of three independent samples.  
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4.7 Expression of the BCL2 gene is increased in HT-29S cells 
 Downstream of integrin α5β1/PI3K/Akt is induction of BCL2 transcription, which 
mediates the pro-survival effect of this pathway[fig. 1.4]125,131,132. We wished to determine if the 
upregulation of integrin α5 and activation of Akt was promoting BCL2 expression in HT-29S, 
allowing these cells to resist serum deprivation. This question was addressed by assaying for the 
expression of BCL2 mRNA by qRT-PCR. We consistently observed a higher level of expression 
of BCL2 in HT-29S versus HT-29 [fig. 4.8], which was determined to be statistically significant 
(p < 0.05). The transcription or stability of the BCL2 mRNA is significantly increased in HT-29S 
cells, consistent with the proposed mechanism. 
 
  
  
67 
 
 
  
Figure 4.9: BCL2 expression in HT-29 and HT-29S cells. 
The expression of the BCL2 gene was measured using SYBR green based qRT-PCR. Reactions 
were performed in triplicate on 25 ng (RNA equivalent) of reverse transcribed cDNA on a 
StepOnePlus Real-Time PCR system (Applied Biosystems). The primers used for these 
experiments are listed in table 6.15. Data is presented as the mean + SEM from four 
independent samples. Statistically significant differences in expression were determined by the 
Mann-Whitney test. * p < 0.05  
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4.8 Inhibition of PI3K sensitizes HT-29S to SN-38 
 To investigate if the increase in integrin α5β1-fibronectin signaling through to PI3K 
might contribute to a CAM-DR effect in the HT-29S cell line, we measured the sensitivity of 
HT-29 and HT-29S cells to SN-38 following disruption of this pathway with the PI3K inhibitor 
LY294002. We began by determining the sensitivity of HT-29 and HT-29S to LY294002 by 
measuring cellular viability at a range of LY249002 doses with the MTT assay. In agreement 
with previous studies141, treatment with LY294002 reduced the proliferation and viability of HT-
29 cells at higher concentrations [fig. 4.9]. HT-29S cells were somewhat (~3-fold) less sensitive 
to LY294002 than HT-29 cells, which may reflect the higher basal activity of PI3K/Akt in these 
cells [fig. 4.9]. The IC50 values of LY294002 were estimated by non-linear regression to be 
5.971 μM for HT-29 and 17.44 μM for HT-29S [table 4.2]. Based on this result and a desire to 
treat the cell lines under comparable conditions, we chose both 5 μM and 10 μM as working 
concentrations for PI3K inhibition experiments, as there was a noticeable effect in both cell lines 
at these doses without extreme toxicity.  
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Figure 4.9. – Effect of LY294002 on HT-29 and HT-29S proliferation. 
96-well plates were seeded with 2000 HT-29 and 2500 HT-29S cells, and incubated at 37°C, 
5% CO2 overnight. Cells were dosed with LY294002 or vehicle-control and incubated for a 
further 96 hours. At the end of this period, an MTT assay was performed. The data presented 
is the mean + SEM of three independent experiments. 
 
Table 4.2: IC50 value of the PI3K inhibitor LY294002 in HT-29 and HT29-S 
70 
 
To test the effect of PI3K inhibition on the response to SN-38 treatment, HT-29 and HT-
29S cells were pre-treated for 1 hour with 5 μM or 10 μM LY294002 (or vehicle-control) and 
subsequently dosed with SN-38. Cells were incubated with SN-38 and LY294002 for a further 
96 hours, and at the end of the exposure period cellular viability was measured by the MTT assay 
Despite the reduction in viability observed for HT-29 cells treated with LY294002, addition of 
the PI3K inhibitor did not seem to have any effect on the response of these cells to SN-38 [fig. 
4.10 A)]. In contrast, PI3K inhibition in HT-29S with LY294002 significantly shifted the SN-38 
dose-response curve [fig. 4.10 B)]. The SN-38 IC50 values were determined by non-linear 
regression of the dose-response data [table 4.3] and compared by an extra sum of squares F-test. 
The IC50 value of SN-38 on HT-29 cells was virtually unaffected by PI3k inhibition [table 4.3], 
and the F-test indicated no statistically significant difference in the SN-38 IC50 values between 
the treatment groups. In contrast, the estimated SN-38 IC50 values for HT-29S decreased from 
358.1 nM in the control group to 39.20 nM with 5 μM LY294002 and 25.46 nM with 10 μM 
LY294002 treatment [table 4.3]. This difference was confirmed to be statistically significant (p = 
0.0004) by the F-test. The LY294002-treated HT-29S cells were therefore more sensitive to SN-
38 than the control group, despite the modest effect of LY294002 treatment on HT-29S in the 
absence of SN-38. Together, these results suggest that PI3K/Akt activation contributes to the 
resistant status of the HT-29S cell line.  
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 Control LY294002 (5 μM) LY294002 (10 μM) 
HT-29 5.005 4.412 7.796 
HT-29S 358.1 39.20 25.46 
 
Figure 4.10: HT-29 and HT-29S SN-38 dose-response in the presence or absence of 
PI3K/Akt pathway inhibition with LY294002. 
A) 96-well plates were seeded with 2000 HT-29 cells, and incubated at 37°C, 5% CO2 
overnight. Cells were dosed with LY294002 or vehicle-control and incubated for one 
hour. At the end of the LY294002 pre-treatment period, cells were dosed with SN-38 
or vehicle-control, and incubated for a final 96-hours. At the end of this period, an 
MTT assay was performed. The data presented is the mean + SEM of five 
independent experiments. The IC50 values of the different groups were compared by 
an extra sum of squares F test. 
B) Same as A), but seeded with 2500 HT-29S instead of HT-29 cells. The IC50 values of 
the different groups were compared by an extra sum of squares F test. 
Table 4.3: Effect of PI3K inhibition on SN-38 response in HT-29 and HT-29S 
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4.9 HT-29S has undergone an epithelial to mesenchymal transition  
 The epithelial to mesenchymal transition (EMT) process has been associated with wound 
healing and cancer progression, and is known to involve a number of proteins and transcription 
factors101,142,143. For example, the EMT-related transcription factors zinc finger E-box binding 
homobox 2 (ZEB2) and twist-related protein 1 (TWIST1) have been demonstrated to promote 
transcription from the ITGA5 gene during EMT in human cancer cell lines144,145. Because of this 
apparent link we wished to determine if there was a change in expression of these and other 
EMT-related genes between our parental and drug resistant cells. We addressed this question by 
performing qRT-PCR on HT-29 and HT-29S cDNA using a panel of primers directed against a 
panel of EMT-related genes. We found that a number of interesting changes in EMT gene 
expression have occurred during the acquisition of drug resistance. A small (approximately 2.7 
fold) but statistically significant (p < 0.05) increase in expression of the ZEB2 transcript was 
observed in HT-29S versus HT-29 cDNA samples. The very minimal expression of the Snail 
family zinc finger 2 gene (SNAI2) in HT-29 was dramatically increased in HT-29S cells (p < 
0.05) [fig 4.11]. Similarly, we were consistently unable to detect any TWIST1 in HT-29 but 
detected a strong expression in HT-29S [fig. 4.11]. Expression of the junction plakoglobin (JUP) 
and vimentin (VIM) genes also appeared to be trending towards increased expression in HT-29S, 
but these differences were not statistically significant [fig. 4.11]. JUP however was almost 
significant, with p = 0.0571. Similarly, the zinc-finger E-box binding homobox 1 (ZEB1) gene 
expression appeared to be substantially decreased in HT-29S, but this was not statistically 
significant [fig. 4.11]. The expression of two other EMT genes, Snail family zinc finger 1 
(SNAI1) and the tight junction protein 1 (TJP1), were not substantially altered between HT-29 
and HT-29S cells [fig. 4.11].   
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Figure 4.12: EMT gene expression in HT29 and HT29-S.  
The expression of various genes was measured using SYBR green based qRT-PCR. 
Reactions were performed in triplicate on 25 ng (RNA equivalent) of reverse transcribed 
cDNA on a StepOnePlus Real-Time PCR system (Applied Biosystems). The primers used for 
these experiments are listed in table 6.15. Samples were normalized for loading differences 
against the housekeeping gene RPL27. Data is presented as the mean + SEM from four 
independent samples. Statistically significant differences in expression were determined by 
the Mann-Whitney test. * p < 0.05. n.d. – None detected. 
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Chapter 5: Discussion 
5.1 Summary 
 The data presented here demonstrate that dramatic alterations in CRC cell-ECM 
interactions occur upon acquisition of SN-38 resistance. This change is mediated by a substantial 
upregulation of the integrin α5 subunit leading to an increased formation of functional integrin 
α5β1 receptor. It is likely that this receptor then promotes the formation of a complex fibronectin 
network within resistant cell colonies, and the subsequent adhesion of α5β1 to the fibronectin 
matrix activates an intracellular PI3K/Akt signalling pathway that opposes chemotherapy-
mediated apoptosis induction through increased BCL2 expression.  
5.2 Morphology of SN-38-resistant cells 
 The cellular morphology of HT-29 cells is dramatically altered by acquisition of SN-38 
resistance, with HT-29S cells adopting features characteristically associated with more advanced, 
aggressive cancers. For example, the HT-29 line grows as flat monolayers that are typical of 
epithelial cells or a well-differentiated tumour, but HT-29S does not. Instead these cells form the 
vertical outgrowths that we have named “nodules” [fig. 4.1 A)]. Since HT-29S no longer appears 
restricted to monolayer growth, it suggests that they may have lost contact inhibition. Loss of 
contact inhibition has also been associated with EMT146, suggesting that an EMT may have 
occurred in HT-29S. This possibility is further discussed in section 5.9. 
 A second distinct change is an increase in the nuclear diameter [fig. 4.1B)] and 
dysmorphia [fig. 4.1 C)] of HT-29S compared to HT-29. Enlarged and irregularly-shaped nuclei 
are a well-described feature of progression in many types of cancer (reviewed in 147), further 
suggesting that our drug-resistant CRC cell line represents a more advanced, aggressive disease 
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than the parental cells. There are many possible causes for alterations in nuclear size and shape 
during cancer progression including mutation or deletion of genes encoding the nuclear lamina, 
or altered chromatin organization147, however one of particular interest in our cell lines is the 
effect of ECM contacts. It has been previously reported that integrin-mediated adhesion and 
spreading over ECM substrates such as fibronectin can cause alteration in nuclear shape and 
promote the release of calcium from the endoplasmic reticulum (ER) into the cytoplasm and 
nucleus133. Deformation of nuclei is likely mediated by actin bundles connecting integrin-ECM 
contacts to the nucleus148. Calcium release can activate various kinases including CaMK IV, 
which participates in the pro-survival fibronectin-integrin α5β1 signalling pathway [fig. 1.4]. 
Therefore while there are many potential explanations for the altered nuclear morphology of HT-
29S, one possibility that is consistent with our data is that integrin α5β1 adhesion to fibronectin 
exerts mechanical stress that alters nuclei shape and encourages calcium release from the ER, 
which in turn activates CAMK IV and subsequently promotes BCL2 expression through 
activation of CREB and NFκB.  
5.3 Interactions between HT-29S and fibronectin 
 We have demonstrated that HT-29 cell interactions with a particular component of the 
ECM, fibronectin, are significantly altered along with resistance to SN-38. We observed an 
increased accumulation of fibronectin in HT-29S spheroids [fig. 4.2 A)] which in some cases 
took the appearance of a fibrous, matrix-like structure [fig. 4.2 B)]. This increased fibronectin 
matrix formation in HT-29S may contribute to the altered morphology of these cells by 
providing a scaffold for nodule formation. The increased accumulation of fibronectin in HT-29S 
coincided with an increased adhesive capacity of these cells for that ECM glycoprotein [fig. 4.3 
A)]. HT2-29S cells that adhered to fibronectin adopted a stretched or spreading morphology that 
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was absent in adherent HT-29 cells, which remained spherical [fig. 4.3 B)]. Both the increased 
adhesion and the spreading morphology of HT-29S were reversible by a soluble GRGDSP 
peptide but not a control GRADSP peptide at the same concentration [fig. 4.3 A) and B)]. The 
interaction between HT-29S and fibronectin is therefore RGD-dependent and likely involves an 
αIIb, α5, α8, or αV integrin, but not an α4 or α9149. The spreading morphology of HT-29S 
suggests that the resistant cells were migrating over the fibronectin coating, and may also suggest 
that the resistant cells are able to exert the necessary force on fibronectin to unfold the soluble 
dimer form of the glycoprotein; a necessary step in the construction of a fibronectin matrix and 
one that can be mediated by integrin α5β1103.  
5.4 Expression of integrin subunits in HT-29 and HT-29S 
 Numerous changes were observed in the expression of integrin family members between 
HT-29 and HT-29S cell lines. The significance of those changes are discussed in sections 5.4.1 
to 5.4.6, and are summarized in figure 5.1.  
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Figure 5.1: Functional significance of integrin expression changes on HT-29S cells. 
The expression changes of individual integrin subunits in HT-29S relative to HT-29. Green 
arrows indicate an increased expression of the integrin in HT-29S, while red arrows indicate a 
reduced expression. Possible functional implications of these expression changes are presented 
below each subunit. 
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5.4.1 Integrin α4 
 Integrin α4β1is able to bind fibronectin at a distinct site from the RGD-dependent 
integrins, and in doing can suppress signalling pathways activated by integrin α5β1 ligation to 
fibronectin86,87, meaning the effect of integrin α5 upregulation in HT-29S may depend on the 
activity of this subunit. Integrin α4 was detected in both HT-29 and HT-29S [fig. 4.4 A)] but its 
expression did not appear to be substantially altered. Somewhat surprisingly however, the only 
band detected for this protein corresponded to a molecular weight of approximately 55 kDa; 
much lower than the expected molecular size of approximately 150 kDa. It has been previously 
demonstrated that integrin α4 can be cleaved to a number fragments, including a 55 kDa 
fragment, which is not capable of forming a functional heterodimer with integrin β1150. 
Therefore, it appears that integrin α4 expression does not change between HT-29 and HT-29S, 
and indeed it likely does not form a functional receptor to have any impact on cellular behaviour 
in either cell line.  
5.4.2 Integrin α5 
The most notable result of the analysis of integrin expression in HT-29 and HT-29S cells 
by western blot was the change in integrin α5 expression [fig. 4.4 A)]. It has been well 
documented that this subunit is not normally expressed in HT-29 and that ectopic expression of 
integrin α5 on HT-29 can have profound effects on the behaviour of these cells108,109,116,124,125. 
Consistent with these results, we were could not detect any expression of integrin α5 in the 
parental HT-29 cell line. It appears that the upregulation of integrin α5 in HT-29S is due to an 
increased abundance of ITGA5 mRNA [fig. 4.4 C)], which could reflect an increase in 
transcription from the ITGA5 gene or an increase in the stability of the mRNA. We favour the 
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former due to an observed upregulation of transcription factors that may drive ITGA5 expression, 
which will be discussed further in section 5.9. 
Immunofluorescence studies on HT-29 and HT-29S monolayers confirmed the 
upregulation of integrin α5 in the resistant cells [fig. 4.4 A)]. These experiments also revealed a 
fibrous staining pattern for integrin α5 at the edges of cells [fig. 4.5 A) and B)], which may 
represent integrins binding along ECM fibrils. Similar patterns were observed in early 
immunofluorescent studies of integrins, co-localizing with fibronectin and actin bundles62. 
Fibronectin is the most likely ECM protein to form the postulated fibrils, because (i) it is the only 
known ECM ligand of integrin α5149, (ii) our data show that fibrils of this glycoprotein 
accumulates in HT-29S spheroids, and (iii) HT-29S cells gain an adhesive capacity for 
fibronectin. These observations therefore suggest that integrin α5 on HT-29S cells, as part of the 
integrin α5β1 heterodimer, binds fibronectin, which would in turn initiate downstream signalling 
pathways. To the best of our knowledge, this is the first description of spontaneous expression of 
integrin α5 in CRC cells as a result of chemotherapy resistance. The implications of integrin α5 
expression in HT-29S behaviour and response to SN-38 will be discussed further throughout this 
chapter.  
5.4.3 Integrins α6 and β4 
Another very interesting change in integrin expression between HT-29 and HT-29S 
involved the α6 subunit. There appeared to be a modest decrease in the expression of this subunit 
the resistant cell line [fig. 4.4 A)]. More interestingly however, there was also a shift in migration 
of the integrin α6 band, implying a reduced molecular weight of the protein in HT-29S. Such a 
reduced-molecular-weight-variant of integrin α6 (called α6p) has been described in a number of 
cancer cell lines, and appears to be a result of proteolytic cleavage of a β-barrel ligand-binding 
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extracellular domain151–153. This cleavage event is mediated by urokinase-type plasminogen 
activator (uPA) but seemingly not by matrix metalloproteinases (MMPs) at arginines 594 and 
595152,153. Generation of integrin α6p is associated with increased invasion into and migration 
over laminin, a major constituent of the basement membrane, and thus appears to be a pro-cancer 
event153. Furthermore, while the full-length form of integrin α6 can be found in both normal and 
malignant prostate tissue, α6p appears to be largely cancer-specific152. The cleavage of integrin 
α6 to α6p in HT-29S would suggest that our SN-38 resistant cell line may be more aggressive 
and invasive than the parental cells, however this remains to be determined. This increase in 
aggressive behaviour may result from a loss of EMT-suppression by a laminin-integrin α6 
interaction154. The possibility that HT-29S has undergone an EMT is discussed further in section 
5.9. We cannot definitively conclude from these western blot results alone that this cleavage 
event is actually occurring. In order to prove that integrin α6p is formed by our resistant cell 
population, we could attempt to block the cleavage event by treating HT-29S with a uPA 
inhibitor such as amiloride hydrochloride or UK122. We would expect to see an increase in the 
molecular weight of the integrin α6 band in HT-29S following treatment with the uPA inhibitor. 
Alternatively, we could isolate and sequence the integrin α6 protein from HT-29 and HT-29S 
cells to determine if cleavage has occurred in HT-29S.  
 Further suggesting a reduced activity of integrin α6 is the reduced expression of integrins 
β1 and β4, both of which form heterodimers with α6 (reviewed in 149). In fact, integrin α6 
appears to be the only binding partner for integrin β6. Between the reduced expression of 
integrin β1 and β4, and the possible cleavage of integrin α6, it is very likely that integrin α6 
activity is significantly reduced in HT-29S.   
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5.4.4 Integrin α9 
 The expression of integrin α9 was substantially reduced in HT-29S compared to parental 
HT-29 cells [fig. 4.4 A)]. It has previously been reported that integrin α9 is not expressed in HT-
29155. The source of the discrepancy between these findings and our own is not clear; our results 
consistently and unambiguously (n = 3) showed a strong expression of integrin α9 in the HT-29 
line. Integrin α9 binds to the ECM protein tenascin-C in an RGD-independent manner156,157. It 
may also bind to a splice variant of fibronectin via the EIIIA domain to promote lymphatic valve 
formation during development79 and in adult lymphatic valves may promote the egress of 
lymphocytes from the lymph nodes81.  
5.4.5 Integrins αV, β3, and β5 
 Integrin αV’s expression pattern was the opposite of that of integrin α5; it was highly 
expressed in HT-29 samples (in agreement with previous studies109) but absent in HT-29S [fig. 
4.4 A)]. Furthermore, the expression of three β subunits which form heterodimers with integrin 
αV, integrins β1, β3, and β5, was substantially reduced in HT-29S.  
The αVβ1 and αVβ3 heterodimers are both able to mediate adhesion to vitronectin and 
fibronectin149. Integrin αVβ6 can also bind to fibronectin and may be the main fibronectin 
receptor in parental HT-29 cells158. Integrin αVβ5 binds solely to vitronectin149. Despite this 
difference in ligand specificities, all of the αV integrins exhibit RGD-dependent binding149 
Unlike integrin α5β1, αVβ1 and αVβ3 are unable to construct a fibronectin matrix99,159. Integrins 
αVβ1 and αVβ6 are also unable to promote spreading over a fibronectin substrate158,159. The αV 
integrins have however been implicated in promoting spheroid formation in ovarian cancer cell 
lines through an interaction with vitronectin160, thus the malformed spheroids of HT-29S may 
possibly be attributed in part to the loss of αV integrins. Cancer aggression has also been linked 
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to αV integrins through angiogenesis and secretion of MMPs 2 and 9161,162. The loss of integrin 
αV expression may therefore reduce some behaviours associated with cancer aggression in HT-
29S but may also free up integrin β1 to form the fibronectin receptor with integrin α5.   
5.4.6 Integrin β1 
Integrin β1 expression was dramatically reduced in HT-29S [fig. 4.4 A)]. This was somewhat 
unexpected as integrin β1 is a very important member of the family and interacts with many of 
the α subunits to form a large number of receptors149. It is also the sole binding partner for 
integrin α5, and therefore the upregulation of integrin α5 is meaningless if no integrin β1 is 
available to form the full fibronectin receptor149. However, it was not entirely absent in these 
cells [fig. 4.4 B)] and as HT-29S exhibits behaviours suggestive of active integrin α5β1, 
including fibronectin adhesion and matrix formation, Akt activation, and resistance to serum 
deprivation, it seems that sufficient integrin β1 is retained in HT-29S to form the α5β1 receptor. 
The reduced expression of integrins α9 and αV may also help promote the formation of the α5β1 
heterodimer by reducing competition for integrin β1, as these are also binding partners for this 
subunit149.  
5.5 Serum starvation  
 The results of the serum deprivation assays presented in figure 4.6 show the effect of 
serum withdrawal on cell viability. HT-29 cell viability was reduced to approximately 20% of 
control cells, indicating a high dependence on serum [fig. 4.6 A)]. In contrast, HT-29S cell 
viability was only reduced to approximately 70% of control cells [fig. 4.6 A)]. Integrin α5β1 has 
previously been demonstrated to protect against apoptosis induced by serum deprivation124,125,132, 
suggesting that the upregulated integrin α5 in the HT-29S cell line may form functional α5β1 
receptors.  
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 The morphology of HT-29 and HT-29S cells following serum deprivation further 
supports a loss of serum dependence in the HT-29S cell line. HT-29 cells that have been 
deprived of serum are sparse and have largely lost their usual cobblestone appearance; many of 
these cells have instead adopted a “rounded-up” morphology [fig. 4.6 B)]. A similar effect 
occurs during apoptotic but not necrotic cell death, suggesting that, consistent with previous 
studies, HT-29 cells may be dying by apoptosis during serum deprivation124,125. In contrast, 
serum-starved HT-29S cells are slightly less confluent than their control counterparts but 
otherwise appear equally healthy [fig. 4.6 B)]. The small reduction in HT-29S cell viability upon 
serum withdrawal may therefore be a result of a slight reduction of proliferation due to loss of 
serum-derived growth factors, rather than an increase in cell death.  
5.7 Akt activation and upregulation of BCL2 
 The PI3K/Akt pathway forms one branch of the downstream signalling from integrin 
α5β1 activation by fibronectin ligation [fig. 1.4]. We therefore assessed Akt activity in the HT-29 
and HT-29S cell lines, and found that Akt phosphorylation at two amino acid residues (Ser473 
and Thr308) critical for its activity were significantly increased in HT-29S [fig. 4.7]. This result 
is consistent with an increased activity of integrin α5β1 due to the upregulation of integrin α5 
and increased fibronectin matrix formation in HT-29S, however the PI3K/Akt pathway 
contributes to a great number of intracellular signalling pathways. We cannot be certain that the 
increased Akt activity observed in HT-29S is due to integrin α5β1, although the evidence we 
have collected strongly suggests that it is. To support integrin α5β1 activity in HT-29S, we 
looked at the expression of a target gene of this pathway, BCL2, which also requires FAK and 
CAMK IV signalling dependent upon integrin α5β1 [fig. 1.4]. 
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As can be seen in figure 4.8, BCL2 is upregulated in HT-29S compared to HT-29. 
However, the upregulation of BCL2 mRNA is quite modest- only approximately three-fold 
greater than HT-29. It may seem that this is too modest an increase to mediate the substantial 
SN-38 resistance of HT-29S, but there are a number of factors that should be considered. To 
begin, the change in BCL2 expression was measured at the gene level. The small increase in 
BCL2 mRNA may be greatly amplified during translation to a much greater increase in Bcl-2 
protein. It should also be noted that another study which observed the pro-survival effect of Bcl-
2 during serum deprivation also saw only a very minor increase in Bcl-2 expression, even at the 
protein level125. This as well as our own results is likely reflective of the nature of the Bcl-2 
family; many pro- and anti-apoptotic proteins maintaining a delicate balance between cell 
survival and death. A small increase in an anti-apoptotic family member such as Bcl-2 may be 
sufficient to sway the balance towards survival, even in the face of significant cell stress.  
 The concept of Bcl-2 family balance raises another issue- the mere upregulation of BCL2 
expression does not necessarily prove a net anti-apoptotic effect. It is quite possible that there is 
a concomitant rise in the expression of one of the pro-apoptotic family members, cancelling out 
the upregulation of BCL2 and leaving HT-29S no more protected against apoptosis than HT-29. 
To address this issue we could look further downstream in the apoptotic pathway by western 
blotting for markers of apoptosis induction, such as caspase 3 cleavage.  
5.8 Sensitization to SN-38 by PI3K inhibition 
 If fibronectin and integrin α5β1 are supporting HT-29S survival during chemotherapy 
with SN-38, then interfering with this signalling pathway should restore HT-29S sensitivity to 
the drug. Previous studies have successfully interfered with the fibronectin receptor’s pro-
survival functions by shutting down the downstream PI3K/Akt pathway126, presumably at least 
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in part by inhibiting the expression of BCL2. By treating HT-29 and HT-29S with the small 
molecule PI3K inhibitor LY294002, we found that the response to SN-38 was enhanced in the 
resistant population but unchanged in the parental cells [fig. 4.10 and table 4.3], supporting our 
hypothesis that resistance in HT-29S is mediated by activation of the fibronectin-integrin α5β1 
signalling pathway outlined in fig. 1.4. The SN-38 IC50 value for HT-29S changed from 
approximately 358 nM in the vehicle control group to 39.2 nM with 5 μM LY294002 and 25.4 
nM with 10 μM LY294002 [table 4.3], indicating a dose-dependence to the sensitization. HT-
29S cells treated with 10 μM LY294002 were still more resistant to the drug than the parental 
cells, which had an IC50 value of 5.01 nM in the control group. This may simply indicate that 
some PI3K/Akt activity remained after LY294002 treatment, and that a higher dose of the 
inhibitor may completely restore SN-38 sensitivity. We cannot exclude the possibility though 
that HT-29S cells are have additional pro-survival mechanisms in place that act in concert with 
the fibronectin-integrin α5β1-PI3K/Akt pathway to resist the effects of SN-38. The doses of 
LY294002 were limited to 10 μM because higher dose would be excessively toxic to the parental 
HT-29 cell line [fig. 4.09 and table 4.2].  
5.9 Epithelial to mesenchymal transition in HT-29S 
 The conversion of an epithelial cell to a mesenchymal phenotype through an EMT occurs 
in a number of normal conditions including during embryonic development and wound healing 
(reviewed in 163). Unfortunately, this process is also frequently co-opted by cancer cells and is 
associated with cancer aggression, invasiveness, and chemotherapy resistance164–166. The 
expression of the EMT-promoting genes SNAI2, TWIST1, and ZEB2 are upregulated in the HT-
29S cell line, suggesting that an EMT has occurred in these cells [fig. 4.11]. Furthermore, the 
upregulation of integrin α5 in HT-29S is likely EMT-related, as the expression of two EMT 
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transcription factors that promote ITGA5 transcription, TWIST1 and ZEB2, are increased in our 
drug-resistant cell line144,145. Interestingly, many of the pro-cancer effects of a Twist1-driven 
EMT, such as increased invasive and migratory abilities, have been demonstrated to be mediated 
through integrin α5-dependent activation of FAK and c-Jun N-terminal kinase (JNK)145. It has 
also been reported that integrin α5β1 will construct pericellular fibronectin matrices as part of an 
EMT program143, much like the fibronectin matrices we observe in HT-29S spheroids.  
 Upregulation of SNAI2 in HT-29S was the other significant change in EMT gene 
expression that we observed in this set of experiments. SNAI2 encodes the transcription factor 
Slug which can also promote invasion and migration. Expression of SNAI2 can been 
demonstrated to be driven by both fibronectin167 and the PI3K/Akt pathway168, which suggests 
that the fibronectin-integrin α5β1 signalling axis described in HT-29S may also be responsible 
for driving SNAI2 expression. This would not be entirely novel, as integrin α5β1 has been 
previously been implicated to driving EMTs in other systems154,169 as have other integrins167,170. 
To the best of our knowledge however, integrin α5β1 has not previously been directly implicated 
in regulating SNAI2 expression.  
 If an EMT has occurred in HT-29S, it likely has additional effects on their behaviour 
beyond promoting ITGA5 transcription. EMTs are often considered an invasion and metastasis-
enabling step in cancer progression163, and so we may expect that our HT-29S cell line may be 
more aggressive than HT-29. In recent years however it has been demonstrated that multiple 
types of EMT are possible163,171 and that some of these may not coincide with increased 
migration172. Therefore, we expect that the presumed EMT in HT-29S likely has increased the 
aggression and metastatic potential of this cell line, in part due to an upregulation of integrin α5, 
but this remains to be investigated. A combination of in vitro cell-based assays and animal 
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models should be performed to answer these questions. The changes in integrin expression in 
HT-29S and potential involvement of integrin α5β1 in the EMT experienced by these cells 
suggest that any changes in migratory and invasive potential of these cells will be highly 
dependent on the ligands with which they are presented. Invasion and migration assays should 
therefore be performed with a variety of ECM substrates. Given the upregulation of integrin 
α5β1 in HT-29S, it is reasonable to expect that fibronectin may uniquely promote invasion and 
migration of these cells. 
 It appears that an EMT program has occurred in HT-29S, and that through upregulation 
of TWIST1 and ZEB2, it may have induced ITGA5 expression. The α5β1 receptor then mediates 
the construction and ligation to a fibronectin matrix, activating a pro-survival program that 
upregulates BCL2 and possibly also SNAI2 through PI3K/Akt activation. A residual question in 
this model is then what event initiated the EMT and induction of TWIST1 and ZEB2. 
Transcription of the TWIST1 mRNA has been found to be driven by a number of factors, 
including steroid receptor coactivator 1 (SRC-1)173, signal transducer and activator of 
transcription 3 (STAT3)174, hypoxia-inducible factor 1 α (HIF-1α)175, or canonical wingless-type 
(Wnt) signalling176. With so many transcriptional regulators involved, it is difficult to speculate 
on how the EMT process was initiated in HT-29S cells. Resolving the mechanisms of EMT 
induction in these cells will be an important goal in continuing the study of the SN-38 resistant 
phenotype. The proposed effects of the EMT in HT-29S cells are outlined in figure 5.2. 
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5.10 Limitations 
 A major limitation of the work described within this document is that it has been 
performed entirely in vitro. We cannot at this time be certain that the HT-29S cell line would 
retain its SN-38 resistance in vivo, and it should therefore be a priority going forward to study 
this cell line in mouse models. Doing so would also allow us to ask questions about how the 
Figure 5.2: Proposed functions of EMT in HT-29S cells. 
A possible role for the upregulation of the EMT genes TWIST1, ZEB2, and SNAI2 induced by 
SN-38 in HT-29S, and their crossover with integrin α5β1 activity. 
These images are adapted from Servier Medical Art by Servier, licensed under CC BY 3.0. 
90 
 
acquisition of drug resistance and in particular the EMT that HT-29S appears to have undergone 
have affected the aggression and metastatic capacity of this cell line.  
 We have compiled strong evidence but as of yet have not conclusively proven the role of 
integrin α5 in HT-29S resistance against SN-38. To do so we would need to either ectopically 
force the expression of the integrin in HT-29, or disrupt its expression in HT-29S. We have made 
several attempts at generating HT-29 transfectants either stably or transiently expressing a GFP-
tagged integrin α5, however HT-29 is a notoriously difficult-to-transfect cell line and we have to 
date been unsuccessful. Our attempts at transfection have thus far been with the chemical agent 
X-tremeGENE HP DNA Transfection Reagent (Roche), however it may be necessary to attempt 
other means of transfection, such as lentiviral-mediated.  
This resistance program was only studied in a single CRC cell line. Another SN-38 
resistant cell line was created in parallel with HT-29S; HCT116-S derived from the CRC cell 
line HCT116. Despite also being highly resistant to SN-38, this cell line did not appear to share 
HT-29S’s mechanism of resistance. HCT116-S instead appeared to resist the drug through an 
upregulation of the BCRP efflux pump. Although it would be interesting to see this same 
resistance mechanism replicated in other CRC cell lines, it is altogether not surprising there is 
variability in the mechanism of resistance. Cancers are a highly heterogeneous set of diseases, 
and even patients with the same primary tumour type may differ substantially at the cellular or 
genomic level. HT-29 and HCT116 differ in their cellular morphology, ploidy, p53 status, and 
many other traits. Some of the major differences between these cell lines are shown in table 5.1, 
with data from the American Type Culture Collection (ATCC) and a 2013 study on genetic 
features of CRC cell lines177.  
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5.11 Significance of the work 
 The contribution of integrin α5 to cancer progression has historically been controversial, 
with either pro- and anti-cancer functions being ascribed to the α5β1 receptor. Even recent 
studies that are specifically on CRC report conflicting data, with integrin α5 expression both 
increasing and decreasing during cancer progression110,112. Our demonstration of integrin α5 
contributing to acquired SN-38 resistance through a CAM-DR mechanism provides support to 
the pro-CRC role for this protein, and does so in the context of a disease progression model that 
is relevant to human patients undergoing therapy. Interestingly, we also observed the reduced 
proliferation rate observed in other studies as a presumed anti-cancer effect of integrin 
α5β1106,108. We argue that this reduced proliferation rate should be considered, at most, a small 
cost in overall cell population vigour for the acquisition of drug resistance. In fact, a transient 
reduced proliferation rate during chemotherapy treatment may have a pro-tumour effect, as the 
majority of our traditional chemotherapy agents target the unregulated proliferation of cancer 
 HT-29 HCT-116 
Origin 
Primary CRC 
adenocarcinoma 
Primary CRC 
carcinoma 
Patient 44 year old male 48 year old female 
Microsatellite status Stable Unstable 
Modal Chromosome Number 71 45 
BRAF V600E Wild-type 
KRAS Wild-type G13D 
PIK3CA P449T H1047R 
TP53 R273H Wild-type 
 
Table 5.1: HT-29 and HCT116 characteristics. 
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cells. When the selective pressure of the chemotherapy is removed, the cancer might 
downregulate integrin α5 expression and resume its rapid growth. This fits well with patients 
who experience cancer recurrence several months or even years after chemotherapy.  
 Although several integrin α5β1 inhibitors are currently being developed and clinically 
tested, they are uniformly being proposed as anti-angiogenic agents. The role of integrin α5β1 in 
angiogenesis is well established and angiogenesis is a well-validated target in CRC, however our 
results suggest that integrin α5β1’s role in cancer is not limited to angiogenesis. Ongoing 
preclinical and clinical studies with integrin α5β1 inhibitors should focus on determining if there 
is any additional benefit, beyond the anti-angiogenic effect, of integrin α5β1 inhibition in 
advanced CRC patients who have already failed chemotherapy with irinotecan. Such studies 
should combine integrin α5β1 inhibitors with irinotecan or other chemotherapy agents, as our 
results indicate that inhibition of the fibronectin-integrin α5β1 pathway without additional 
chemotherapy will be ineffective in reducing viability of CRC cells that have upregulated 
integrin α5 [fig. 4.10 and table 4.3].  
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Appendix 
A.1 Buffers 
 
  NaCl 1370 mM 
KCl 27 mM 
Na2HPO4 100 mM 
KH2PO4 18 mM 
MilliQ H2O  
pH 7.4  
 
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
 
Table A.2: PBS  
 
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
 
NaCl 150 mM 
Tris-HCl 50 mM 
Triton X-100 1% 
Na-deoxycholate 0.5% 
SDS 0.1% 
EDTA 1 mM 
MilliQ H2O  
pH 7.4  
 
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
 
Table A.1: RIPA buffer  
 
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
 
  
 
  
  
  
  
  
  
  
 
Table A.3: 4X NuPAGE LDS 
Sample Buffer (Life Technologies) 
 
Tris-HCl 106 mM 
Tris base 141 mM 
Lithium dodecyl 
sulfate (LDS) 
2% 
Glycerol 10% 
EDTA 0.51 mM 
SERVA Blue G250 0.22 mM 
Phenol red 0.175 mM 
pH 8.5 
 
 
  
  
  
 
  
  
  
  
Glycine 192 mM 
Tris base 25 mM 
SDS 0.1% 
MilliQ H2O  
 
  
  
  
  
  
  
  
  
  
 
  
  
  
Table A.4: Running buffer 
 
Acrylamide/bisacrylamide 8% 
Tris-HCl, pH 8.8 0.4 M 
SDS 0.10% 
Ammonium persulfate 0.05% 
TEMED 0.07% 
MilliQ H2O  
 
  
  
  
  
Table A.5: Polyacrylamide resolving 
gel 
 
Acrylamide/bisacrylamide 4% 
Tris-HCl, pH 6.8 0.13 M 
SDS 0.1% 
Ammonium persulfate 0.05% 
TEMED 0.1% 
MilliQ H2O  
 
 
  
  
  
  
  
Table A.6: Polyacrylamide stacking gel 
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Glycine 192 mM 
Tris base 25 mM 
MeOH 20% 
MilliQ H2O  
 
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
 
Table A.7: Transfer buffer 
 
Tris base 50 mM 
NaCl 150 mM 
Tween-20 0.2% 
MilliQ H2O  
pH to 7.6  
 
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
 
Table A.8: TBS-T 
 
NaCl 1370 mM 
KCl 27 mM 
Na2HPO4 100 mM 
KH2PO4 18 mM 
CaCl2·2H2O 1 mM 
MgCl2·6H2O 0.5 mM 
MilliQ H2O  
pH 7.4  
 
Table A.10: PBS with Ca2+ and 
Mg2+ 
 
PFA 3.7 mg 
MilliQ H2O 9 mL 
5 N NaOH 20 μL 
10X PBS 1 mL 
5 N HCl 20 μL 
 
Combine PFA and MilliQ. Add NaOH to 
assist in solubilisation, and stir with gentle 
heating. Add 10X PBS. Once PFA is fully 
dissolved, add HCl to neutralize the 
NaOH.  
Table A.9: 3.7% PFA 
 
Ethanol 70% 
Concentrated HCl 1% 
MilliQ H2O  
 
Table A.11: Acid alcohol 
 
 
KHCO3 20 mM 
Mg2SO4 166 mM 
Distilled H2O  
 
Table A.12: Scot’s tap water 
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A.2 Antibody information 
Target Clonality Host 
Species 
Application Manufacturer 
Akt C67E7 Rabbit Western blot Cell Signalling 
Akt p-
Ser473 
D9E Rabbit Western blot Cell Signalling 
Akt p-
Thr308 
D25E6 Rabbit Western blot Cell Signalling 
Fibronectin F1  Rabbit Immunofluorescence  Abcam 
Integrin α4 D2E1 Rabbit Western blot Cell Signalling 
Integrin α5 Polyclonal 
#4705 
Rabbit Western blot, 
immunofluorescence 
Cell Signalling 
Integrin α6 Polyclonal 
#4750 
Rabbit Western blot Cell Signalling 
Integrin 
α9β1 
Y9A2 Mouse Western blot, 
immunofluorescence 
Abcam 
Integrin αV Polyclonal 
#4711 
Rabbit Western blot Cell Signalling 
Integrin β1 D2E5 Rabbit Western blot Cell Signalling 
Integrin β3 D7X3P Rabbit Western blot Cell Signalling 
Integrin β4 Polyclonal 
#4707 
Rabbit Western blot Cell Signalling 
Integrin β5 D24A5 Rabbit  Western blot Cell Signalling 
 
Table A.13: Primary Antibodies 
Table A.14: Loading control, secondary, and isotype antibodies 
Target Clonality Host Species Application Manufacturer Conjugate 
GAPDH 1 E6 D9 Mouse Western blot Proteintech HRP 
None DA1E Rabbit Immunofluorescence 
(isotype) 
Cell signalling None 
Rabbit 
IgG 
Polyclonal 
A-11034 
Donkey Immunofluorescence  Life 
Technologies 
Alexa Fluor 488 
Rabbit 
IgG 
Polyclonal 
#7074 
Goat Western blot Cell Signalling HRP 
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A.3 Primer information 
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 Ideal Primer Characteristics 
Melting Temperature As close to 60°C as possible 
Amplicon Length 50-200 base pairs 
GC Content (%) 30-80. Avoid GC rich stretches 
3' Terminus No more than 2 G or C in the last 5 bps 
Runs Avoid runs of >4 identical bases (especially G) 
Position One primer in each pair must span an exon-exon junction 
Splice variants Picks up all variants with equal-sized amplicons 
Single Nucleotide 
Polymorphism (SNP) 
Avoid SNPs within primer-binding sequences 
Hairpin Formation ΔG > -2 kCal/mol 
Homodimer formation 
Internal: ΔG > -6 kCal/mol  
3’ Terminus: ΔG > -5 kCal/mol 
Heterodimer formation 
Internal: ΔG > -6 kCal/mol  
3’ Terminus: ΔG > -5 kCal/mol 
Table A.16: Primer design characteristics  
